<html><body><document>
<type>S-3
<sequence>1
<filename>d201932ds3.htm
<description>S-3
<text>
<title>S-3</title>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>As filed with the Securities and Exchange Commission on November&#160;9, 2020 </b></p>
<p align="right" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Registration No.&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </b></p>
<p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p>
<p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p align="center" style="margin-top:1pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>UNITED STATES </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><b>Washington, D.C. 20549 </b></p> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center>
<p style="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center> <p align="center" style="margin-top:2pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>FORM <font style="white-space:nowrap">S-3</font> </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>REGISTRATION STATEMENT </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><b><i>UNDER </i></b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><b><i>THE
SECURITIES ACT OF 1933 </i></b></p> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:2pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><b>AVEO Pharmaceuticals, Inc. </b></p>
<p align="center" style="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>(Exact name of registrant as specified in its charter) </b></p> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" width="100%">
<tr>
<td width="50%"></td>
<td valign="bottom" width="1%"></td>
<td width="48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td align="center" valign="top"><b>Delaware</b></td>
<td valign="bottom">&#160;</td>
<td align="center" valign="top"><b><font style="white-space:nowrap">04-3581650</font></b></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td align="center" valign="top"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>(State or other jurisdiction of</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman"><b>incorporation or organization)</b></p></td>
<td valign="bottom">&#160;</td>
<td align="center" valign="top"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>(I.R.S. Employer</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman"><b>Identification Number)</b></p></td></tr>
</table> <p align="center" style="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>30 Winter Street </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Boston, Massachusetts 02108 </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>(857) <font style="white-space:nowrap">400-0101</font> </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </b></p>
<p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Erick Lucera </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Chief
Financial Officer </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>AVEO Pharmaceuticals, Inc. </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>30 Winter Street </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Boston,
Massachusetts 02108 </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>(857) <font style="white-space:nowrap">400-0101</font> </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>(Name, address, including zip code, and telephone number, including area code, of agent for service) </b></p>
<p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b><i>Copy to: </i></b></p> <p align="center" style="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Cynthia T.
Mazareas, Esq. </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Wilmer Cutler Pickering Hale and Dorr LLP </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>60 State Street </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Boston,
Massachusetts 02109 </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>(617) <font style="white-space:nowrap">526-6000</font> </b></p>
<p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p style="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman"><b>Approximate date of commencement of proposed sale to the public</b>: From time to time after this registration statement becomes effective.
</p> <p style="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check
the following box.&#160;&#160;&#9744; </p> <p style="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous
basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&#160;&#160;&#9746; </p>
<p style="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </p>
<p style="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </p> <p style="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following
box.&#160;&#160;&#9744; </p> <p style="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D.
filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.&#160;&#160;&#9744; </p>
<p style="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<font style="white-space:nowrap">non-accelerated</font> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company,&#148; and &#147;emerging growth company&#148; in Rule <font style="white-space:nowrap">12b-2</font> of the Exchange Act.<sup style="font-size:85%; vertical-align:top"> </sup> </p>
<p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" width="100%">
<tr>
<td width="13%"></td>
<td valign="bottom" width="1%"></td>
<td width="67%"></td>
<td valign="bottom" width="1%"></td>
<td width="16%"></td>
<td valign="bottom" width="1%"></td>
<td width="1%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td valign="bottom">Large&#160;accelerated&#160;filer</td>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#9744;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">Accelerated&#160;filer</td>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#9746;</td></tr>
<tr style="font-size:1pt">
<td height="2"></td>
<td colspan="2" height="2"></td>
<td colspan="2" height="2"></td>
<td colspan="2" height="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td valign="bottom">Non-accelerated filer</td>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#9744;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">Smaller&#160;reporting&#160;company</td>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#9746;</td></tr>
<tr style="font-size:1pt">
<td height="2"></td>
<td colspan="2" height="2"></td>
<td colspan="2" height="2"></td>
<td colspan="2" height="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td valign="bottom"></td>
<td valign="bottom">&#160;</td>
<td valign="bottom"></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">Emerging&#160;growth&#160;company</td>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#9744;</td></tr>
</table> <p style="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;&#9744; </p>
<p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>CALCULATION OF REGISTRATION FEE </b></p> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" width="100%">
<tr>
<td width="40%"></td>
<td valign="bottom" width="1%"></td>
<td width="14%"></td>
<td valign="bottom" width="1%"></td>
<td width="14%"></td>
<td valign="bottom" width="1%"></td>
<td width="14%"></td>
<td valign="bottom" width="1%"></td>
<td width="14%"></td></tr>
<tr style="font-size:1px; ">
<td colspan="9" valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td align="center" style="BORDER-TOP:1px solid #000000" valign="bottom"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Title of Each Class of</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman"><b>Securities to be Registered</b></p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td align="center" nowrap="" style="BORDER-TOP:1px solid #000000" valign="bottom"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Amount</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>to be</b></p> <p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman"><b>Registered<sup style="font-size:85%; vertical-align:top">(1)</sup></b></p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td align="center" nowrap="" style="BORDER-TOP:1px solid #000000" valign="bottom"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Proposed</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Maximum</b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Offering
Price</b></p> <p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman"><b>Per Unit<sup style="font-size:85%; vertical-align:top">(1)</sup></b></p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td align="center" nowrap="" style="BORDER-TOP:1px solid #000000" valign="bottom"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Proposed</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Maximum</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman"><b>Aggregate<br/>Offering Price<sup style="font-size:85%; vertical-align:top">(1)</sup></b></p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td align="center" nowrap="" style="BORDER-TOP:1px solid #000000" valign="bottom"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>Amount of</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman"><b>Registration Fee</b></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="BORDER-TOP:1px solid #000000" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Common Stock, par value $0.001 per share</p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="BORDER-TOP:1px solid #000000" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Preferred Stock, par value $0.001 per share</p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="BORDER-TOP:1px solid #000000" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Debt Securities</p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="BORDER-TOP:1px solid #000000" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Warrants</p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="BORDER-TOP:1px solid #000000" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Units</p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="BORDER-TOP:1px solid #000000" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Total</p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td align="center" nowrap="" style="BORDER-TOP:1px solid #000000" valign="bottom">$300,000,000</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td align="center" nowrap="" style="BORDER-TOP:1px solid #000000" valign="bottom">$32,730<sup style="font-size:85%; vertical-align:top">(2)</sup></td></tr>
<tr style="font-size:1px; ">
<td colspan="9" valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td></tr>
<tr style="font-size:1px; ">
<td colspan="9" valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" width="100%">
<tr style="page-break-inside:avoid">
<td align="left" valign="top" width="4%">(1)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; ">Pursuant to Form <font style="white-space:nowrap">S-3</font> General Instruction II.D information is not
required to be included. An indeterminate amount of the securities of each identified class is being registered as may from time to time be offered hereunder at indeterminate prices, along with an indeterminate number of securities that may be
issued upon exercise, settlement, exchange or conversion of securities offered or sold hereunder as shall have an aggregate initial offering price not to exceed $300,000,000. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;), this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities.
Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities. In addition, the total amount to be registered and the proposed maximum aggregate offering price are
estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act. </p></td></tr></table>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" width="100%">
<tr style="page-break-inside:avoid">
<td align="left" valign="top" width="4%">(2)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; ">Pursuant to Rule 415(a)(6) under the Securities Act, the securities hereunder include the unsold securities
previously registered pursuant to the Registration Statement on Form <font style="white-space:nowrap">S-3</font> originally filed on November&#160;30, 2017 and declared effective on December&#160;15, 2017, File Number
<font style="white-space:nowrap">333-221837</font> (the &#147;Prior Registration Statement&#148;). The Prior Registration Statement registered the offer and sale of shares of common stock, shares of preferred stock, debt securities, warrants and
units having an aggregate initial offering price not to exceed $200,000,000, of which an aggregate of $68,805,172 remain unsold as of the date of filing of this registration statement (the &#147;Unsold Securities&#148;), which the registrant has
determined to include in this registration statement. The registrant paid a filing fee of $8,566.25 (calculated at the prior filing fee rate) relating to the Unsold Securities under the Prior Registration Statement, and no additional filing fee is
due with respect to the Unsold Securities in connection with the filing of this registration statement. The registrant is also registering new securities on this registration statement with an aggregate initial offering price of $231,194,828 (the
&#147;New Securities&#148;), which aggregate offering price is not specified as to each class of securities. A filing fee of $25,224 with respect to the New Securities is being paid in connection with the filing of this registration statement. To
the extent that, after the filing date hereof and prior to the effectiveness of this registration statement, the registrant sells any Unsold Securities pursuant to the Prior Registration Statement, the registrant will identify in a <font style="white-space:nowrap">pre-effective</font> amendment to this registration statement the updated amount of Unsold Securities from the Prior Registration Statement to be included in this registration statement pursuant to Rule 415(a)(6) and the
updated amount of New Securities to be registered on this registration statement. Pursuant to Rule 415(a)(6), the offering of the Unsold Securities under the Prior Registration Statement will be deemed terminated as of the date of effectiveness of
this registration statement. </p></td></tr></table> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center>
<p style="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center> <p style="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><b>The Registrant hereby amends
this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in
accordance with Section&#160;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission acting pursuant to said Section&#160;8(a), may determine. </b></p>
<p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p>
<p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>EXPLANATORY NOTE </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This registration statement contains two prospectuses: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a base prospectus which covers the offering, issuance and sale by us of up to $300,000,000 of our common stock,
preferred stock, debt securities, warrants and/or units; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a sales agreement prospectus covering the offering, issuance and sale by us of up to $31,794,031 of our common
stock that may be sold from time to time under a sales agreement with Leerink Partners LLC (now known as SVB Leerink LLC). </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base
prospectus will be specified in a prospectus supplement to the base prospectus. The sales agreement prospectus immediately follows the base prospectus. The common stock that may be offered, issued and sold by us under the sales agreement prospectus
is included in the $300,000,000 of securities that may be offered, issued and sold by us under the base prospectus. </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><font color="#ff4338"><b>The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction
where the offer or sale is not permitted. </b></font></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><font color="#ff4338"><b>Subject to completion, dated November&#160;9, 2020 </b></font></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>PROSPECTUS </b></p>
<p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><b>$300,000,000 </b></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p align="center" style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="https://www.sec.gov/Archives/edgar/data/0001325879/000119312520289207/g201932g11k45.jpg"/>
</p> <p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Common Stock </b></p>
<p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Preferred Stock </b></p> <p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Debt
Securities </b></p> <p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Warrants </b></p>
<p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Units </b></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer
and sell securities from time to time in one or more offerings of up to $300,000,000 in aggregate offering price. This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We
will provide the specific terms of these securities in supplements to this prospectus. The prospectus supplements will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information
contained in this document. You should read this prospectus and any applicable prospectus supplement before you invest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer
these securities in amounts, at prices and on terms determined at the time of offering. The securities may be sold directly to you, through agents, or through underwriters and dealers. If agents, underwriters or dealers are used to sell the
securities, we will name them and describe their compensation in a prospectus supplement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq
Capital Market under the symbol AVEO. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><b>Investing in these securities involves significant risks. See &#147;Risk Factors&#148; included in any accompanying prospectus supplement
and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities. </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. We urge you to read the entire
prospectus, any amendments or supplements, any free writing prospectuses, and any documents incorporated by reference carefully before you make your investment decision. </p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </b></p> <p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>The date of this
prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2020 </b></p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc"></a>TABLE OF CONTENTS </b></p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr>
<td width="97%"></td>
<td valign="bottom" width="1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc201932_1">ABOUT THIS PROSPECTUS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">1</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc201932_2">WHERE YOU CAN FIND MORE INFORMATION</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">2</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc201932_3">INCORPORATION BY REFERENCE</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">2</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc201932_4">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">3</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc201932_5">ABOUT AVEO PHARMACEUTICALS, INC.</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">4</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc201932_6">USE OF PROCEEDS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">5</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc201932_7">DESCRIPTION OF DEBT SECURITIES</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">6</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc201932_8">DESCRIPTION OF CAPITAL STOCK</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">15</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc201932_9">DESCRIPTION OF WARRANTS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">22</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc201932_10">DESCRIPTION OF UNITS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">23</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc201932_11">FORMS OF SECURITIES</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">24</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc201932_12">PLAN OF DISTRIBUTION</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">26</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc201932_13">LEGAL MATTERS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">29</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc201932_14">EXPERTS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">29</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
</table>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc201932_1"></a>ABOUT THIS PROSPECTUS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, which we refer to as the
&#147;SEC,&#148; utilizing a &#147;shelf&#148; registration process. Under this shelf registration process, we may from time to time sell any combination of the securities described in this prospectus in one or more offerings for an aggregate
initial offering price of up to $300,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities we may offer.
Each time we sell securities, we will provide one or more prospectus supplements that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information contained in this
prospectus or in any documents that we have incorporated by reference into this prospectus and, accordingly, to the extent inconsistent, information in this prospectus is superseded by the information in the prospectus supplement. You should read
both this prospectus and the accompanying prospectus supplement together with the additional information described under the heading &#147;Where You Can Find More Information&#148; beginning on page 2 of this prospectus. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement
or in any related free writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the
solicitation of an offer to buy any securities other than the securities described in this prospectus or such accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which
such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their
respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise indicates, references in this prospectus to &#147;AVEO,&#148; &#147;the Company,&#148; &#147;we,&#148;
&#147;us&#148; and &#147;our&#148; refer, collectively, to AVEO Pharmaceuticals, Inc., a Delaware corporation, and our subsidiaries. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-1- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc201932_2"></a>WHERE YOU CAN FIND MORE INFORMATION </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#146;s website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at http://www.aveooncology.com/. Our website is not a part of this prospectus and is
not incorporated by reference in this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. This
prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our
consolidated subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and
are qualified by reference to these filings. You should review the complete document to evaluate these statements. </p> <p align="center" style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc201932_3">
</a>INCORPORATION BY REFERENCE </b></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference much of the information we file with the SEC, which
means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are
incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all
of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the
documents listed below (File <font style="white-space:nowrap">No.&#160;001-34655)</font> and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act (in
each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the
registration statement until the offering of the securities under the registration statement is terminated or completed: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on <a href="http://www.sec.gov/Archives/edgar/data/1325879/000156459020011145/aveo-10k_20191231.htm">Form
 <font style="white-space:nowrap">10-K</font></a> for the fiscal year ended December&#160;31, 2019, including the information specifically incorporated by reference into the Annual Report on Form <font style="white-space:nowrap">10-K</font> from our
definitive proxy statement for the 2020 Annual Meeting of Stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly Reports on Form <font style="white-space:nowrap">10-Q</font> for the fiscal quarters ended <a href="http://www.sec.gov/Archives/edgar/data/1325879/000156459020019921/aveo-10q_20200331.htm">March&#160;31,
 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/1325879/000156459020038899/aveo-10q_20200630.htm">June&#160;
30, 2020</a> and <a href="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1325879/000156459020052556/aveo-10q_20200930.htm">September&#160;30, 2020</a>; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on Form <font style="white-space:nowrap">8-K</font> filed on <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520002244/d863683d8k.htm">January&#160;6,
 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520035652/d881309d8k.htm">February&#160;13, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520042086/d806743d8k.htm">February&#160;
19, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520153095/d936328d8k.htm">May&#160;27, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520155052/d889663d8k.htm">May&#160;29, 2020</a> (Item
8.01 only), <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520157210/d904464d8k.htm">June&#160;1, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520165801/d929481d8k.htm">June&#160;
10, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520169515/d885511d8k.htm">June&#160;15, 2020</a> (Item 8.01 only), <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520171457/d942122d8k.htm">June&#160;
17, 2020</a> and <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520240516/d80039d8k.htm">September&#160;8, 2020</a>; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our Registration Statement on <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312510051398/d8a12b.htm">Form
 <font style="white-space:nowrap">8-A</font></a> filed on March&#160;9, 2010, including any amendments or reports filed for the purpose of updating such description. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </p>
<p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AVEO Pharmaceuticals, Inc. </p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30
Winter Street </p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02108 </p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Investor Relations </p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(857) <font style="white-space:nowrap">400-0101</font> </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-2- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc201932_4"></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated by reference in this prospectus include &#147;forward-looking statements&#148; within the
meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Exchange Act. These statements are based on current expectations, estimates, forecasts and projections about the industry in
which we operate and the beliefs and assumptions of our management. Words such as &#147;expects,&#148; &#147;anticipates,&#148; &#147;targets,&#148; &#147;goals,&#148; &#147;projects,&#148; &#147;intends,&#148; &#147;plans,&#148;
&#147;believes,&#148; &#147;seeks,&#148; &#147;estimates,&#148; &#147;continues,&#148; and &#147;may&#148; and variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, any statements
that refer to projections regarding our future operating results and financial position, our business strategy, our prospects and other objectives of our operations are forward-looking statements. You are cautioned that these forward-looking
statements are only predictions and are subject to risks, uncertainties and assumptions, including risks related to the impact of the <font style="white-space:nowrap">COVID-19</font> pandemic on our clinical trials and other business operations as
well as those inherent in pharmaceutical research and development, such as adverse results in our clinical development activities, our ability to obtain any necessary financing to conduct our planned activities, decisions made by the U.S. Food and
Drug Administration and other regulatory authorities with respect to the development and commercialization of our drug candidates, our ability to obtain, maintain and enforce intellectual property rights for our drug candidates, our dependence on
our existing and future strategic partners, and other risk factors that are referenced in the section of any accompanying prospectus supplement entitled &#147;Risk Factors.&#148; You should also carefully review the risk factors and cautionary
statements described in the other documents we file from time to time with the SEC, specifically our most recent Annual Report on Form <font style="white-space:nowrap">10-K,</font> our Quarterly Reports on Form
<font style="white-space:nowrap">10-Q</font> and our Current Reports on Form <font style="white-space:nowrap">8-K.</font> We undertake no obligation to revise or update any forward-looking statements, except to the extent required by law. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-3- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc201932_5"></a>ABOUT AVEO PHARMACEUTICALS, INC. </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Company Overview </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. Our strategy is to focus our resources toward development and commercialization of our product candidates in North America
while leveraging partnerships to support development and commercialization in other geographies. Our lead candidate is tivozanib (FOTIVDA<sup style="font-size:85%; vertical-align:top">&#174;</sup>), a vascular endothelial growth factor receptor
tyrosine kinase inhibitor. FOTIVDA<sup style="font-size:85%; vertical-align:top">&#174;</sup> is approved through our development partner EUSA Pharma (UK) Limited in the European Union, the United Kingdom, Norway, New Zealand and Iceland for the
first-line treatment of adult patients with advanced renal cell carcinoma. We are working to develop and commercialize tivozanib in North America as a treatment for renal cell carcinoma and hepatocellular carcinoma. We are also studying tivozanib in
combination with immune checkpoint inhibitors for the treatment of renal cell carcinoma and hepatocellular carcinoma in phase 2 clinical trials. We have previously reported promising early clinical data on ficlatuzumab, a hepatocyte growth factor
inhibitory antibody, in squamous cell carcinoma of the head and neck, acute myeloid leukemia and pancreatic cancer. Our earlier stage pipeline under development includes <font style="white-space:nowrap">AV-203,</font> an anti-ErbB3 monoclonal
antibody, as a potential oncology treatment; <font style="white-space:nowrap">AV-380,</font> a humanized IgG1 inhibitory monoclonal antibody targeting growth differentiation factor 15, a divergent member of the
<font style="white-space:nowrap">TGF-&#223;</font> family, for the potential treatment of cancer cachexia; and <font style="white-space:nowrap">AV-353,</font> which targets the Notch 3 pathway, as a potential oncology treatment. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Company Information </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated
in Delaware on October&#160;19, 2001 as GenPath Pharmaceuticals, Inc. and changed our name to AVEO Pharmaceuticals, Inc. on March&#160;1, 2005. Our principal executive offices are located at 30 Winter Street, Boston, Massachusetts 02108, and our
telephone number is (857) <font style="white-space:nowrap">400-0101.</font> Our website address is www.aveooncology.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included
our website address in this prospectus solely as an inactive textual reference. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-4- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc201932_6"></a>USE OF PROCEEDS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless
otherwise indicated in the applicable prospectus supplement. General corporate purposes may include working capital and capital expenditures; research and development expenses, including clinical trial costs; general and administrative expenses;
repayment and refinancing of debt; commercialization expenses; and potential business development opportunities. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad
discretion over the allocation of net proceeds. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-5- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc201932_7"></a>DESCRIPTION OF DEBT SECURITIES </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer debt securities which may be senior or subordinated. We refer to the senior debt securities and the subordinated debt securities
collectively as debt securities. The following description summarizes the general terms and provisions of the debt securities. We will describe the specific terms of the debt securities and the extent, if any, to which the general provisions
summarized below apply to any series of debt securities in the prospectus supplement relating to the series and any applicable free writing prospectus that we authorize to be delivered. When we refer to &#147;we,&#148; &#147;our,&#148;
&#147;us,&#148; &#147;AVEO,&#148; and &#147;the Company&#148; in this section, we mean AVEO Pharmaceuticals, Inc., excluding, unless the context otherwise requires or as otherwise expressly stated, our subsidiaries. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue senior debt securities from time to time, in one or more series under a senior indenture to be entered into between us and a
senior trustee to be named in a prospectus supplement, which we refer to as the senior trustee. We may issue subordinated debt securities from time to time, in one or more series under a subordinated indenture to be entered into between us and a
subordinated trustee to be named in a prospectus supplement, which we refer to as the subordinated trustee. The forms of senior indenture and subordinated indenture are filed as exhibits to the registration statement of which this prospectus forms a
part. The senior indenture and the subordinated indenture are referred to individually as an indenture and together as the indentures and the senior trustee and the subordinated trustee are referred to individually as a trustee and together as the
trustees. This section summarizes some of the provisions of the indentures and is qualified in its entirety by the specific text of the indentures, including definitions of terms used in the indentures. Wherever we refer to particular sections of,
or defined terms in, the indentures, those sections or defined terms are incorporated by reference in this prospectus or the applicable prospectus supplement. You should review the indentures that are filed as exhibits to the registration statement
of which this prospectus forms a part for additional information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither indenture will limit the amount of debt securities that we may
issue. The applicable indenture will provide that debt securities may be issued up to an aggregate principal amount authorized from time to time by us and may be payable in any currency or currency unit designated by us or in amounts determined by
reference to an index. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>General </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
senior debt securities will constitute our unsecured and unsubordinated general obligations and will rank equally in right of payment with our other unsecured and unsubordinated obligations. The subordinated debt securities will constitute our
unsecured and subordinated general obligations and will be junior in right of payment to our senior indebtedness (including senior debt securities), as described under the heading &#147;&#151;Certain Terms of the Subordinated Debt
Securities&#151;Subordination.&#148; The debt securities will be structurally subordinated to all existing and future indebtedness and other liabilities of our subsidiaries unless such subsidiaries expressly guarantee such debt securities. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities will be our unsecured obligations. Any secured debt or other secured obligations will be effectively senior to the debt
securities to the extent of the value of the assets securing such debt or other obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement and/or
free writing prospectus will include any additional or different terms of the debt securities of any series being offered, including the following terms: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and type of the debt securities; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be senior or subordinated debt securities, and, with respect to any subordinated
debt securities the terms on which they are subordinated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initial aggregate principal amount of the debt securities; </p></td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-6- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which we will sell the debt securities; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date or dates of the debt securities and the right, if any, to extend such date or dates;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates, if any, at which the debt securities will bear interest, or the method of determining such
rate or rates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates from which such interest will accrue, the interest payment dates on which such interest will be
payable or the method of determination of such dates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the right, if any, to extend the interest payment periods and the duration of that extension;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner of paying principal and interest and the place or places where principal and interest will be payable;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions for a sinking fund, purchase fund or other analogous fund, if any; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any redemption dates, prices, obligations and restrictions on the debt securities; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency, currencies or currency units in which the debt securities will be denominated and the currency,
currencies or currency units in which principal and interest, if any, on the debt securities may be payable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any conversion or exchange features of the debt securities; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be subject to the defeasance provisions in the indenture; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in definitive or global form or in definitive form only upon
satisfaction of certain conditions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be guaranteed as to payment or performance; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any special tax implications of the debt securities; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any events of defaults or covenants in addition to or in lieu of those set forth in the indenture; and
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other material terms of the debt securities. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we refer to &#147;principal&#148; in this section with reference to the debt securities, we are also referring to &#147;premium, if
any.&#148; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time, without notice to or the consent of the holders of any series of debt securities, create and issue
further debt securities of any such series ranking equally with the debt securities of such series in all respects (or in all respects other than (1)&#160;the payment of interest accruing prior to the issue date of such further debt securities or
(2)&#160;the first payment of interest following the issue date of such further debt securities). Such further debt securities may be consolidated and form a single series with the debt securities of such series and have the same terms as to status,
redemption or otherwise as the debt securities of such series. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may present debt securities for exchange and you may present debt
securities for transfer in the manner, at the places and subject to the restrictions set forth in the debt securities and the applicable prospectus supplement. We will provide you those services without charge, although you may have to pay any tax
or other governmental charge payable in connection with any exchange or transfer, as set forth in the indenture. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt securities may bear
interest at a fixed rate or a floating rate. Debt securities bearing no interest or interest at a rate that at the time of issuance is below the prevailing market rate (original issue discount securities) may be sold at a discount below their stated
principal amount. U.S. federal income tax considerations applicable to any such discounted debt securities or to certain debt securities issued at par which are treated as having been issued at a discount for U.S. federal income tax purposes will be
described in the applicable prospectus supplement. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-7- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities with the principal amount payable on any principal payment
date, or the amount of interest payable on any interest payment date, to be determined by reference to one or more currency exchange rates, securities or baskets of securities, commodity prices or indices. You may receive a payment of principal on
any principal payment date, or a payment of interest on any interest payment date, that is greater than or less than the amount of principal or interest otherwise payable on such dates, depending on the value on such dates of the applicable
currency, security or basket of securities, commodity or index. Information as to the methods for determining the amount of principal or interest payable on any date, the currencies, securities or baskets of securities, commodities or indices to
which the amount payable on such date is linked and certain related tax considerations will be set forth in the applicable prospectus supplement. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Certain Terms of the Senior Debt Securities </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Covenants. </i>Unless we indicate otherwise in a prospectus supplement with respect to a particular series of senior debt securities, the
senior debt securities will not contain any financial or restrictive covenants, including covenants restricting either us or any of our subsidiaries from incurring, issuing, assuming or guaranteeing any indebtedness secured by a lien on any of our
or our subsidiaries&#146; property or capital stock, or restricting either us or any of our subsidiaries from entering into sale and leaseback transactions. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Consolidation, Merger and Sale of Assets. </i>Unless we indicate otherwise in a prospectus supplement with respect to a particular series
of senior debt securities, we may not consolidate with or merge into any other person, in a transaction in which we are not the surviving corporation, or convey, transfer or lease our properties and assets substantially as an entirety to any person,
in either case, unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successor entity, if any, is a U.S. corporation, limited liability company, partnership or trust;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successor entity assumes our obligations on the senior debt securities and under the senior indenture;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after giving effect to the transaction, no default or event of default shall have occurred and be
continuing; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have delivered to the senior trustee an officer&#146;s certificate and an opinion of counsel, each stating
that the consolidation, merger, conveyance, transfer or lease and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture, comply with the senior indenture and all conditions precedent provided for
in the senior indenture relating to such transaction have been complied with. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions described in the bullets above do not
apply (1)&#160;to our consolidation with or merging into one of our affiliates, if our board of directors determines in good faith that the purpose of the consolidation or merger is principally to change our state of incorporation or our form of
organization to another form or (2)&#160;if we merge with or into a single direct or indirect wholly-owned subsidiary of ours. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The surviving business
entity will succeed to, and be substituted for, us under the senior indenture and the senior debt securities and, except in the case of a lease, we shall be released from all obligations under the senior indenture and the senior debt securities.
</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>No Protection in the Event of a Change in Control. </i>Unless we indicate otherwise in a prospectus supplement with respect to a
particular series of senior debt securities, the senior debt securities will not contain any provisions that may afford holders of the senior debt securities protection in the event we have a change in control or in the event of a highly leveraged
transaction (whether or not such transaction results in a change in control). </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-8- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Events of Default. </i>Unless we indicate otherwise in a prospectus supplement with
respect to a particular series of senior debt securities, the following are events of default under the senior indenture with respect to senior debt securities of each series: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to pay interest on any senior debt securities of such series when due and payable, if that default
continues for a period of 30 days (or such other period as may be specified for such series); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to pay principal on the senior debt securities of such series when due and payable whether at maturity,
upon redemption, by declaration or otherwise (and, if specified for such series, the continuance of such failure for a specified period); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance of or breach of any of our covenants or agreements in the senior indenture applicable
to senior debt securities of such series, other than a covenant breach which is specifically dealt with elsewhere in the senior indenture, and that default or breach continues for a period of 90 days after we receive written notice from the trustee
or from the holders of 25% or more in aggregate principal amount of the senior debt securities of such series; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain events of bankruptcy or insolvency, whether or not voluntary; and </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other event of default provided for in such series of senior debt securities as may be specified in the
applicable prospectus supplement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The default by us under any other debt, including any other series of debt
securities, is not a default under the senior indenture. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default other than an event of default specified in the fourth
bullet point above occurs with respect to a series of senior debt securities and is continuing under the senior indenture, then, and in each such case, either the trustee or the holders of not less than 25% in aggregate principal amount of such
series then outstanding under the senior indenture (each such series voting as a separate class) by written notice to us and to the trustee, if such notice is given by the holders, may, and the trustee at the request of such holders shall, declare
the principal amount of and accrued interest on such series of senior debt securities to be immediately due and payable, and upon this declaration, the same shall become immediately due and payable. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default specified in the fourth bullet point above occurs and is continuing, the entire principal amount of and accrued
interest on each series of senior debt securities then outstanding shall automatically become immediately due and payable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless
otherwise specified in the prospectus supplement relating to a series of senior debt securities originally issued at a discount, the amount due upon acceleration shall include only the original issue price of the senior debt securities, the amount
of original issue discount accrued to the date of acceleration and accrued interest, if any. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon certain conditions, declarations of
acceleration may be rescinded and annulled and past defaults may be waived by the holders of a majority in aggregate principal amount of all the senior debt securities of such series affected by the default, each series voting as a separate class.
Furthermore, subject to various provisions in the senior indenture, the holders of a majority in aggregate principal amount of a series of senior debt securities, by notice to the trustee, may waive a continuing default or event of default with
respect to such senior debt securities and its consequences, except a default in the payment of principal of or interest on such senior debt securities (other than any such default in payment resulting solely from an acceleration of the senior debt
securities) or in respect of a covenant or provision of the senior indenture which cannot be modified or amended without the consent of the holders of each such senior debt security. Upon any such waiver, such default shall cease to exist, and any
event of default with respect to such senior debt securities shall be deemed to have been cured, for every purpose of the senior indenture; but no such waiver shall extend to any subsequent or other default or event of default or impair any right
consequent thereto. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-9- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in aggregate principal amount of a series of senior debt
securities may direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to such senior debt securities. However, the trustee may
refuse to follow any direction that conflicts with law or the senior indenture, that may involve the trustee in personal liability or that the trustee determines in good faith may be unduly prejudicial to the rights of holders of such series of
senior debt securities not joining in the giving of such direction and may take any other action it deems proper that is not inconsistent with any such direction received from holders of such series of senior debt securities. A holder may not pursue
any remedy with respect to the senior indenture or any series of senior debt securities unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder gives the trustee written notice of a continuing event of default; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of such series of senior debt securities make a written
request to the trustee to pursue the remedy in respect of such event of default; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requesting holder or holders offer the trustee indemnity satisfactory to the trustee against any costs,
liability or expense; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not comply with the request within 60 days after receipt of the request and the offer of
indemnity; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">during such <font style="white-space:nowrap">60-day</font> period, the holders of a majority in aggregate
principal amount of such series of senior debt securities do not give the trustee a direction that is inconsistent with the request. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations, however, do not apply to the right of any holder of a senior debt security of any affected series to receive payment of the
principal of and interest on such senior debt security in accordance with the terms of such debt security, or to bring suit for the enforcement of any such payment in accordance with the terms of such debt security, on or after the due date for the
senior debt securities, which right shall not be impaired or affected without the consent of the holder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The senior indenture requires
certain of our officers to certify, on or before a fixed date in each year in which any senior debt security is outstanding, as to their knowledge of our compliance with all covenants, agreements and conditions under the senior indenture. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Satisfaction and Discharge</i>. We can satisfy and discharge our obligations to holders of any series of debt securities if: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have paid or caused to be paid the principal of and interest on all senior debt securities of such series
(with certain limited exceptions) when due and payable; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we deliver to the senior trustee for cancellation all senior debt securities of such series theretofore
authenticated under the senior indenture (with certain limited exceptions); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all senior debt securities of such series have become due and payable or will become due and payable within one
year (or are to be called for redemption within one year under arrangements satisfactory to the senior trustee) and we deposit in trust an amount of cash or a combination of cash and U.S. government or U.S. government agency obligations (or in the
case of senior debt securities denominated in a foreign currency, foreign government securities or foreign government agency securities) sufficient to make interest, principal and any other payments on the debt securities of that series on their
various due dates; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and if, in any such case, we also pay or cause to be paid all other sums payable under the senior indenture, as and
when the same shall be due and payable and we deliver to the senior trustee an officer&#146;s certificate and an opinion of counsel, each stating that these conditions have been satisfied. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under current U.S. federal income tax law, the deposit and our legal release from the debt securities would be treated as though we took back
your debt securities and gave you your share of the cash and debt securities or </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-10- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bonds deposited in trust. In that event, you could recognize gain or loss on the debt securities you give back to us. Purchasers of the debt securities should consult their own advisers with
respect to the tax consequences to them of such deposit and discharge, including the applicability and effect of tax laws other than the U.S.&#160;federal income tax law. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Defeasance. </i>Unless the applicable prospectus supplement provides otherwise, the following discussion of legal defeasance and covenant
defeasance will apply to any series of debt securities issued under the indentures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Legal Defeasance</i>. We can legally release
ourselves from any payment or other obligations on the debt securities of any series, called &#147;legal defeasance&#148;, if certain conditions are met, including the following: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We deposit in trust for your benefit and the benefit of all other direct holders of the debt securities of the
same series cash or a combination of cash and U.S. government or U.S. government agency obligations (or, in the case of senior debt securities denominated in a foreign currency, foreign government or foreign government agency obligations) that will
generate enough cash to make interest, principal and any other payments on the debt securities of that series on their various due dates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There is a change in current U.S. federal income tax law or a U.S. Internal Revenue Service ruling that lets us
make the above deposit without causing you to be taxed on the debt securities any differently than if we did not make the deposit and instead repaid the debt securities ourselves when due. Under current U.S. federal income tax law, the deposit and
our legal release from the debt securities would be treated as though we took back your debt securities and gave you your share of the cash and debt securities or bonds deposited in trust. In that event, you could recognize gain or loss on the debt
securities you give back to us. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We deliver to the trustee a legal opinion of our counsel confirming the tax law change or ruling described above.
</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we accomplish legal defeasance, as described above, you would have to rely solely on the trust deposit for repayment
of the debt securities. You could not look to us for repayment in the event of any shortfall. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Covenant Defeasance</i>. Without any
change in current U.S. federal tax law, we can make the same type of deposit described above and be released from some of the covenants in the debt securities, called &#147;covenant defeasance&#148;. In that event, you would lose the protection of
those covenants but would gain the protection of having money and securities set aside in trust to repay the debt securities. In order to achieve covenant defeasance, we must do the following (among other things): </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We must deposit in trust for your benefit and the benefit of all other direct holders of the debt securities of
the same series cash or a combination of cash and U.S. government or U.S. government agency obligations (or, in the case of senior debt securities denominated in a foreign currency, foreign government or foreign government agency obligations) that
will generate enough cash to make interest, principal and any other payments on the debt securities of that series on their various due dates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We must deliver to the trustee a legal opinion of our counsel confirming that under current U.S. federal income
tax law we may make the above deposit without causing you to be taxed on the debt securities any differently than if we did not make the deposit and instead repaid the debt securities ourselves when due. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we accomplish covenant defeasance, you could still look to us for repayment of the debt securities if there were a shortfall in the trust
deposit. In fact, if one of the events of default occurred (such as our bankruptcy) and the debt securities become immediately due and payable, there may be such a shortfall. Depending on the events causing the default, you may not be able to obtain
payment of the shortfall. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-11- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Modification and Waiver. </i>We and the trustee may amend or supplement the senior
indenture or the senior debt securities of any series without the consent of any holder: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to convey, transfer, assign, mortgage or pledge any assets as security for the senior debt securities of one or
more series; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence the succession of a corporation, limited liability company, partnership or trust to us, and the
assumption by such successor of our covenants, agreements and obligations under the senior indenture or to otherwise comply with the covenant relating to mergers, consolidations and sales of assets; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with requirements of the SEC in order to effect or maintain the qualification of the senior indenture
under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants such new covenants, restrictions, conditions or provisions for the protection of the
holders, and to make the occurrence, or the occurrence and continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in the senior indenture or in any supplemental indenture or to
conform the senior indenture or the senior debt securities to the description of senior debt securities of such series set forth in this prospectus or any applicable prospectus supplement; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for or add guarantors with respect to the senior debt securities of any series; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to establish the form or forms or terms of the senior debt securities as permitted by the senior indenture;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment under the senior indenture by a successor trustee, or
to make such changes as shall be necessary to provide for or facilitate the administration of the trusts in the senior indenture by more than one trustee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, change or eliminate any of the provisions of the senior indenture in respect of one or more series of
senior debt securities, provided that any such addition, change or elimination shall (a)&#160;neither (1) apply to any senior debt security of any series created prior to the execution of such supplemental indenture and entitled to the benefit of
such provision nor (2)&#160;modify the rights of the holder of any such senior debt security with respect to such provision or (b)&#160;become effective only when there is no senior debt security described in clause (a)(1) outstanding;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change to the senior debt securities of any series so long as no senior debt securities of such
series are outstanding; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the rights of any holder in any material respect.
</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other amendments and modifications of the senior indenture or the senior debt securities issued may be made, and our
compliance with any provision of the senior indenture with respect to any series of senior debt securities may be waived, with the consent of the holders of a majority of the aggregate principal amount of the outstanding senior debt securities of
each series affected by the amendment or modification (voting as separate series); provided, however, that each affected holder must consent to any modification, amendment or waiver that: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extends the final maturity of any senior debt securities of such series; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduces the principal amount of any senior debt securities of such series; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduces the rate, or extends the time for payment of, interest on any senior debt securities of such series;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduces the amount payable upon the redemption of any senior debt securities of such series;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes the currency of payment of principal of or interest on any senior debt securities of such series;
</p></td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-12- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduces the principal amount of original issue discount securities payable upon acceleration of maturity or the
amount provable in bankruptcy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waives a continuing default in the payment of principal of or interest on the senior debt securities (other than
any such default in payment resulting solely from an acceleration of the senior debt securities); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes the provisions relating to the waiver of past defaults or impairs the right of holders to receive payment
or to institute suit for the enforcement of any payment or conversion of any senior debt securities of such series on or after the due date therefor; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modifies any of the provisions of these restrictions on amendments and modifications, except to increase any
required percentage or to provide that certain other provisions cannot be modified or waived without the consent of the holder of each senior debt security of such series affected by the modification; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adversely affects the right to convert or exchange senior debt securities into common stock or other property in
accordance with the terms of the senior debt securities; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduces the above-stated percentage of outstanding senior debt securities of such series whose holders must
consent to a supplemental indenture or modifies, amends or waives certain provisions of or defaults under the senior indenture. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It shall not be necessary for the holders to approve the particular form of any proposed amendment, supplement or waiver, but it shall be
sufficient if the holders&#146; consent approves the substance thereof. After an amendment, supplement or waiver of the senior indenture in accordance with the provisions described in this section becomes effective, the trustee must give to the
holders affected thereby certain notice briefly describing the amendment, supplement or waiver. Any failure by the trustee to give such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such
amendment, supplemental indenture or waiver. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>No Personal Liability of Incorporators, Stockholders, Officers, Directors. </i>The senior
indenture provides that no recourse shall be had under any obligation, covenant or agreement of ours in the senior indenture or any supplemental indenture, or in any of the senior debt securities or because of the creation of any indebtedness
represented thereby, against any of our incorporators, stockholders, officers or directors, past, present or future, or of any predecessor or successor entity thereof under any law, statute or constitutional provision or by the enforcement of any
assessment or by any legal or equitable proceeding or otherwise. Each holder, by accepting the senior debt securities, waives and releases all such liability. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Concerning the Trustee. </i>The senior indenture provides that, except during the continuance of an event of default, the trustee will not
be liable except for the performance of such duties as are specifically set forth in the senior indenture. If an event of default has occurred and is continuing, the trustee will exercise such rights and powers vested in it under the senior
indenture and will use the same degree of care and skill in its exercise as a prudent person would exercise under the circumstances in the conduct of such person&#146;s own affairs. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The senior indenture and the provisions of the Trust Indenture Act incorporated by reference therein contain limitations on the rights of the
trustee thereunder, should it become a creditor of ours or any of our subsidiaries, to obtain payment of claims in certain cases or to realize on certain property received by it in respect of any such claims, as security or otherwise. The trustee is
permitted to engage in other transactions, provided that if it acquires any conflicting interest (as defined in the Trust Indenture Act), it must eliminate such conflict or resign. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may have normal banking relationships with the senior trustee in the ordinary course of business. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Unclaimed Funds. </i>All funds deposited with the trustee or any paying agent for the payment of principal, premium, interest or additional
amounts in respect of the senior debt securities that remain unclaimed for two </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-13- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
years after the date upon which such amounts became due and payable will be repaid to us. Thereafter, any right of any holder of senior debt securities to such funds shall be enforceable only
against us, and the trustee and paying agents will have no liability therefor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Governing Law. </i>The senior indenture and the senior
debt securities will be governed by, and construed in accordance with, the internal laws of the State of New York. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Certain Terms of the Subordinated
Debt Securities </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the terms of the subordinated indenture and subordinated debt securities relating to subordination or
otherwise as described in the prospectus supplement relating to a particular series of subordinated debt securities, the terms of the subordinated indenture and subordinated debt securities are identical in all material respects to the terms of the
senior indenture and senior debt securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional or different subordination terms may be specified in the prospectus supplement
applicable to a particular series. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Subordination. </i>The indebtedness evidenced by the subordinated debt securities is subordinate to
the prior payment in full of all of our senior indebtedness, as defined in the subordinated indenture. During the continuance beyond any applicable grace period of any default in the payment of principal, premium, interest or any other payment due
on any of our senior indebtedness, we may not make any payment of principal of or interest on the subordinated debt securities (except for certain sinking fund payments). In addition, upon any payment or distribution of our assets upon any
dissolution, <font style="white-space:nowrap">winding-up,</font> liquidation or reorganization, the payment of the principal of and interest on the subordinated debt securities will be subordinated to the extent provided in the subordinated
indenture in right of payment to the prior payment in full of all our senior indebtedness. Because of this subordination, if we dissolve or otherwise liquidate, holders of our subordinated debt securities may receive less, ratably, than holders of
our senior indebtedness. The subordination provisions do not prevent the occurrence of an event of default under the subordinated indenture. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;senior indebtedness&#148; of a person means with respect to such person the principal of, premium, if any, interest on, and any
other payment due pursuant to any of the following, whether outstanding on the date of the subordinated indenture or incurred by that person in the future: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of the indebtedness of that person for money borrowed; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of the indebtedness of that person evidenced by notes, debentures, bonds or other securities sold by that
person for money; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of the lease obligations that are capitalized on the books of that person in accordance with generally
accepted accounting principles; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all indebtedness of others of the kinds described in the first two bullet points above and all lease obligations
of others of the kind described in the third bullet point above that the person, in any manner, assumes or guarantees or that the person in effect guarantees through an agreement to purchase, whether that agreement is contingent or otherwise; and
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all renewals, extensions or refundings of indebtedness of the kinds described in the first, second or fourth
bullet point above and all renewals or extensions of leases of the kinds described in the third or fourth bullet point above; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">unless,
in the case of any particular indebtedness, renewal, extension or refunding, the instrument creating or evidencing it or the assumption or guarantee relating to it expressly provides that such indebtedness, renewal, extension or refunding is not
superior in right of payment to the subordinated debt securities. Our senior debt securities constitute senior indebtedness for purposes of the subordinated indenture. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-14- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc201932_8"></a>DESCRIPTION OF CAPITAL STOCK </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock.
This description is based upon, and is qualified by reference to, our restated certificate of incorporation, as amended, or our certificate of incorporation, our second amended and restated <font style="white-space:nowrap">by-laws,</font> or our <font style="white-space:nowrap">by-laws,</font> and applicable provisions of Delaware corporate law, or the DGCL. You should read our certificate of incorporation, certificate of amendment to our certificate of incorporation and <font style="white-space:nowrap">by-laws,</font> which are filed as exhibits to the registration statement of which this prospectus forms a part, for the provisions that are important to you. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 50,000,000 shares of common stock and 5,000,000 shares of preferred stock. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Common Stock </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Annual Meeting.
</i>Annual meetings of our stockholders are held on the date designated in accordance with our <font style="white-space:nowrap">by-laws.</font> Written notice must be mailed to each stockholder entitled to vote not less than ten nor more than 60
days before the date of the meeting. The presence in person or by proxy of the holders of record of a majority in voting power of our issued and outstanding shares entitled to vote at such meeting constitutes a quorum for the transaction of business
at meetings of the stockholders. Special meetings of the stockholders, unless otherwise prescribed by statute or by our certificate of incorporation, may be called for any purpose or purposes, by the chairman of our board of directors, our board of
directors, or our chief executive officer. Except as may be otherwise provided by applicable law, our certificate of incorporation or our <font style="white-space:nowrap">by-laws,</font> all elections, other than elections of directors, and all
other questions shall be decided by the affirmative vote of the holders of a majority in voting power of the shares of our stock which are present in person or by proxy and voting affirmatively or negatively on such matter. Except as may be provided
by applicable law, our certificate of incorporation or our <font style="white-space:nowrap">by-laws,</font> each director shall be elected by the vote of the plurality of the votes cast by the stockholders entitled to vote with respect to that
director&#146;s election at any meeting for the election of directors at which a quorum is present. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Voting Rights</i>. Each holder of
common stock is entitled to one vote for each share held of record on all matters to be voted upon by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Dividends</i>.
Subject to the rights, powers and preferences of any outstanding preferred stock, and except as provided by law or in our certificate of incorporation, dividends may be declared and paid or set aside for payment on the common stock out of legally
available assets or funds when and as declared by the board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Liquidation, Dissolution and Winding Up</i>. Subject to the
rights, powers and preferences of any outstanding preferred stock, in the event of our liquidation, dissolution or winding up, our net assets will be distributed pro rata to the holders of our common stock. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Other Rights</i>. Holders of the common stock have no right to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convert the stock into any other security; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have the stock redeemed; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase additional stock; or </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain their proportionate ownership interest. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The common stock does not have cumulative voting rights. Holders of shares of the common stock are not required to make additional capital
contributions. Outstanding shares of common stock are <font style="white-space:nowrap">non-assessable.</font> Holders of shares of the common stock are not, and will not be, subject to any liability as stockholders. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-15- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Transfer Agent and Registrar</i>. Computershare Trust Company, N.A. is transfer agent and
registrar for the common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Capital Market under the symbol &#147;AVEO&#148;. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Preferred Stock </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are authorized to
issue &#147;blank check&#148; preferred stock, which may be issued in one or more series upon authorization of our board of directors. Our board of directors is authorized to fix the designations, powers, preferences and the relative, participating,
optional or other special rights and any qualifications, limitations and restrictions of the shares of each series of preferred stock. The authorized shares of our preferred stock are available for issuance without further action by our
stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed. Under our certificate of incorporation, the number of shares of authorized preferred stock may be increased or
decreased (but not below the number of shares outstanding) by the affirmative vote of the holders of a majority of the voting power of the capital stock entitled to vote thereon, voting as a single class. If the approval of our stockholders is not
required for the issuance of shares of our preferred stock, our board may determine not to seek stockholder approval. The specific terms of any series of preferred stock offered pursuant to this prospectus will be described in the prospectus
supplement relating to that series of preferred stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A series of our preferred stock could, depending on the terms of such series,
impede the completion of a merger, tender offer or other takeover attempt. Our board of directors will make any determination to issue preferred shares based upon its judgment as to the best interests of our stockholders. Our directors, in so
acting, could issue preferred stock having terms that could discourage an acquisition attempt through which an acquirer may be able to change the composition of our board of directors, including a tender offer or other transaction that some, or a
majority, of our stockholders might believe to be in their best interests or in which stockholders might receive a premium for their stock over the then-current market price of the stock. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock has the terms described below unless otherwise provided in the prospectus supplement relating to a particular series of
preferred stock. You should read the prospectus supplement relating to the particular series of preferred stock being offered for specific terms, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and stated value per share of the preferred stock and the number of shares offered;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of liquidation preference per share; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price at which the preferred stock will be issued; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate, or method of calculation of dividends, the dates on which dividends will be payable, whether
dividends will be cumulative or noncumulative and, if cumulative, the dates from which dividends will commence to accumulate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any redemption or sinking fund provisions; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the currency of the United States, the currency or currencies including composite currencies in
which the preferred stock is denominated and/or in which payments will or may be payable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any conversion provisions; and </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other rights, preferences, privileges, limitations and restrictions on the preferred stock.
</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock will, when issued, be fully paid and <font style="white-space:nowrap">non-assessable.</font> Unless
otherwise specified in the prospectus supplement, each series of preferred stock will rank equally as to dividends and liquidation rights in all respects with each other series of preferred stock. The rights of holders of shares of each series of
preferred stock will be subordinate to those of our general creditors. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-16- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may, at our option, with respect to any series of preferred stock, elect to offer
fractional interests in shares of preferred stock, and provide for the issuance of depositary receipts representing depositary shares, each of which will represent a fractional interest in a share of the series of preferred stock. The fractional
interest will be specified in the prospectus supplement relating to a particular series of preferred stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Rank</i>. Unless otherwise
specified in the prospectus supplement, the preferred stock will, with respect to dividend rights and rights upon our liquidation, dissolution or winding up of our affairs, rank: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">senior to our common stock and to all equity securities ranking junior to such preferred stock with respect to
dividend rights or rights upon our liquidation, dissolution or winding up of our affairs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a parity with all equity securities issued by us, the terms of which specifically provide that such equity
securities rank on a parity with the preferred stock with respect to dividend rights or rights upon our liquidation, dissolution or winding up of our affairs; and </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">junior to all equity securities issued by us, the terms of which specifically provide that such equity securities
rank senior to the preferred stock with respect to dividend rights or rights upon our liquidation, dissolution or winding up of our affairs. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;equity securities&#148; does not include convertible debt securities. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Dividends</i>. Holders of the preferred stock of each series will be entitled to receive, when, as and if declared by our board of
directors, cash dividends at such rates and on such dates described in the prospectus supplement. Different series of preferred stock may be entitled to dividends at different rates or based on different methods of calculation. The dividend rate may
be fixed or variable or both. Dividends will be payable to the holders of record as they appear on our stock books on record dates fixed by our board of directors, as specified in the applicable prospectus supplement. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends on any series of preferred stock may be cumulative or noncumulative, as described in the applicable prospectus supplement. If our
board of directors does not declare a dividend payable on a dividend payment date on any series of noncumulative preferred stock, then the holders of that noncumulative preferred stock will have no right to receive a dividend for that dividend
payment date, and we will have no obligation to pay the dividend accrued for that period, whether or not dividends on that series are declared payable on any future dividend payment dates. Dividends on any series of cumulative preferred stock will
accrue from the date we initially issue shares of such series or such other date specified in the applicable prospectus supplement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No
dividends may be declared or paid or funds set apart for the payment of any dividends on any parity securities unless full dividends have been paid or set apart for payment on the preferred stock. If full dividends are not paid, the preferred stock
will share dividends pro rata with the parity securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No dividends may be declared or paid or funds set apart for the payment of
dividends on any junior securities unless full dividends for all dividend periods terminating on or prior to the date of the declaration or payment will have been paid or declared and a sum sufficient for the payment set apart for payment on the
preferred stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Liquidation Preference</i>. Upon any voluntary or involuntary liquidation, dissolution or winding up of our affairs,
then, before we make any distribution or payment to the holders of any common stock or any other class or series of our capital stock ranking junior to the preferred stock in the distribution of assets upon any liquidation, dissolution or winding up
of our affairs, the holders of each series of preferred stock shall be entitled to receive out of assets legally available for distribution to stockholders, liquidating distributions in the amount of the liquidation preference per share set forth in
the prospectus supplement, plus any accrued and unpaid dividends thereon. Such dividends will not include any accumulation in respect of unpaid noncumulative dividends for prior dividend periods. Unless otherwise specified in the prospectus
supplement, after payment of </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-17- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the full amount of their liquidating distributions, the holders of preferred stock will have no right or claim to any of our remaining assets. Upon any such voluntary or involuntary liquidation,
dissolution or winding up, if our available assets are insufficient to pay the amount of the liquidating distributions on all outstanding preferred stock and the corresponding amounts payable on all other classes or series of our capital stock
ranking on parity with the preferred stock and all other such classes or series of shares of capital stock ranking on parity with the preferred stock in the distribution of assets, then the holders of the preferred stock and all other such classes
or series of capital stock will share ratably in any such distribution of assets in proportion to the full liquidating distributions to which they would otherwise be entitled. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any such liquidation, dissolution or winding up and if we have made liquidating distributions in full to all holders of preferred stock,
we will distribute our remaining assets among the holders of any other classes or series of capital stock ranking junior to the preferred stock according to their respective rights and preferences and, in each case, according to their respective
number of shares. For such purposes, our consolidation or merger with or into any other corporation, trust or entity, or the sale, lease or conveyance of all or substantially all of our property or assets will not be deemed to constitute a
liquidation, dissolution or winding up of our affairs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Redemption</i>. If so provided in the applicable prospectus supplement, the
preferred stock will be subject to mandatory redemption or redemption at our option, as a whole or in part, in each case upon the terms, at the times and at the redemption prices set forth in such prospectus supplement. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to a series of preferred stock that is subject to mandatory redemption will specify the number of shares of
preferred stock that shall be redeemed by us in each year commencing after a date to be specified, at a redemption price per share to be specified, together with an amount equal to all accrued and unpaid dividends thereon to the date of redemption.
Unless the shares have a cumulative dividend, such accrued dividends will not include any accumulation in respect of unpaid dividends for prior dividend periods. We may pay the redemption price in cash or other property, as specified in the
applicable prospectus supplement. If the redemption price for preferred stock of any series is payable only from the net proceeds of the issuance of shares of our capital stock, the terms of such preferred stock may provide that, if no such shares
of our capital stock shall have been issued or to the extent the net proceeds from any issuance are insufficient to pay in full the aggregate redemption price then due, such preferred stock shall automatically and mandatorily be converted into the
applicable shares of our capital stock pursuant to conversion provisions specified in the applicable prospectus supplement. Notwithstanding the foregoing, we will not redeem any preferred stock of a series unless: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if that series of preferred stock has a cumulative dividend, we have declared and paid or contemporaneously
declare and pay or set aside funds to pay full cumulative dividends on the preferred stock for all past dividend periods and the then current dividend period; or </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if such series of preferred stock does not have a cumulative dividend, we have declared and paid or
contemporaneously declare and pay or set aside funds to pay full dividends for the then current dividend period. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, we will not acquire any preferred stock of a series unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if that series of preferred stock has a cumulative dividend, we have declared and paid or contemporaneously
declare and pay or set aside funds to pay full cumulative dividends on all outstanding shares of such series of preferred stock for all past dividend periods and the then current dividend period; or </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if that series of preferred stock does not have a cumulative dividend, we have declared and paid or
contemporaneously declare and pay or set aside funds to pay full dividends on the preferred stock of such series for the then current dividend period. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, at any time we may purchase or acquire preferred stock of that series (1)&#160;pursuant to a purchase or exchange offer made on the
same terms to holders of all outstanding preferred stock of such series or (2)&#160;by </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-18- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conversion into or exchange for shares of our capital stock ranking junior to the preferred stock of such series as to dividends and upon liquidation. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If fewer than all of the outstanding shares of preferred stock of any series are to be redeemed, we will determine the number of shares that
may be redeemed pro rata from the holders of record of such shares in proportion to the number of such shares held or for which redemption is requested by such holder or by any other equitable manner that we determine. Such determination will
reflect adjustments to avoid redemption of fractional shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the prospectus supplement, we will mail
notice of redemption at least 30 days but not more than 60 days before the redemption date to each holder of record of preferred stock to be redeemed at the address shown on our stock transfer books. Each notice shall state: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the redemption date; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares and series of preferred stock to be redeemed; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the redemption price; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where certificates for such preferred stock are to be surrendered for payment of the
redemption price; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that dividends on the shares to be redeemed will cease to accrue on such redemption date; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the holder&#146;s conversion rights, if any, as to such shares shall terminate; and
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the specific number of shares to be redeemed from each such holder if fewer than all the shares of any series are
to be redeemed. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If notice of redemption has been given and we have set aside the funds necessary for such redemption in
trust for the benefit of the holders of any shares called for redemption, then from and after the redemption date, dividends will cease to accrue on such shares, and all rights of the holders of such shares will terminate, except the right to
receive the redemption price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Voting Rights</i>. Holders of preferred stock will not have any voting rights, except as required by law
or as indicated in the applicable prospectus supplement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided for under the terms of any series of preferred stock,
no consent or vote of the holders of shares of preferred stock or any series thereof shall be required for any amendment to our certificate of incorporation that would increase the number of authorized shares of preferred stock or the number of
authorized shares of any series thereof or decrease the number of authorized shares of preferred stock or the number of authorized shares of any series thereof (but not below the number of authorized shares of preferred stock or such series, as the
case may be, then outstanding). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Conversion Rights</i>. The terms and conditions, if any, upon which any series of preferred stock is
convertible into our common stock will be set forth in the applicable prospectus supplement relating thereto. Such terms will include the number of shares of common stock into which the shares of preferred stock are convertible, the conversion
price, rate or manner of calculation thereof, the conversion period, provisions as to whether conversion will be at our option or at the option of the holders of the preferred stock, the events requiring an adjustment of the conversion price and
provisions affecting conversion in the event of the redemption. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Transfer Agent and Registrar</i>. The transfer agent and registrar for
the preferred stock will be set forth in the applicable prospectus supplement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Effects of Authorized by Unissued Stock </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Authorized but unissued shares of our common stock and preferred stock are available for future issuance without shareholder approval, subject
to any limitations imposed by the listing standards of the Nasdaq Capital </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-19- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefits. The existence of authorized but unissued and unreserved common
stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. In addition, if we issue preferred stock, the issuance could adversely affect the
voting power of holders of common stock and the likelihood that such holder will receive dividend payments and payments upon liquidation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Provisions
of Our Certificate of Incorporation and <font style="white-space:nowrap">By-laws</font> and Delaware Law That May Have Anti-Takeover Effects </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Board of Directors</i>. We do not have a classified board of directors. All of our directors are elected annually. The number of directors
comprising our board of directors is fixed from time to time by the board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Removal of Directors by Stockholders</i>.
Members of our board of directors may be removed from office at any time with or without cause by the affirmative vote of the holders of a majority of the outstanding shares entitled to vote at an election of directors. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Stockholder Nomination of Directors</i>. Our <font style="white-space:nowrap">by-laws</font> provide that a stockholder must notify us in
writing of any stockholder nomination of a director not earlier than the close of business on the 120<sup style="font-size:85%; vertical-align:top">th</sup> day, and not later than the close of business on the 90<sup style="font-size:85%; vertical-align:top">th</sup> day prior to the first anniversary of the preceding year&#146;s annual meeting; provided, that, in the case of the annual meeting of stockholders, if the date of the annual meeting is more than 20
days before or more than 60 days after such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120<sup style="font-size:85%; vertical-align:top">th</sup> day prior to the date
of such annual meeting and not later than the close of business on the later of (x)&#160;the 90<sup style="font-size:85%; vertical-align:top">th</sup> day prior to such annual meeting and (y)&#160;the
10<sup style="font-size:85%; vertical-align:top">th</sup> day following the day on which public announcement of the date of such annual meeting is first made by us. Our <font style="white-space:nowrap">by-laws</font> also provide that, subject to
certain limitations, if a stockholder (or a qualified representative of the stockholder) does not appear at a meeting of stockholders to present a nomination, such nomination shall be disregarded, notwithstanding that proxies in respect of such vote
may have been received by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>No Action By Written Consent</i>. Our certificate of incorporation and our <font style="white-space:nowrap">by-laws</font> provide that our stockholders may not act by written consent and may only act at duly called meetings of stockholders. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Delaware Business Combination Statute.</i> Section&#160;203 of the General Corporation Law of the State of Delaware, which we refer to as
the DGCL, is applicable to us. Section&#160;203 of the DGCL restricts some types of transactions and business combinations between a corporation and a 15% stockholder. A 15% stockholder is generally considered by Section&#160;203 to be a person
owning 15% or more of the corporation&#146;s outstanding voting stock. Section&#160;203 refers to a 15% stockholder as an &#147;interested stockholder.&#148; Section&#160;203 restricts these transactions for a period of three years from the date the
stockholder acquires 15% or more of our outstanding voting stock. With some exceptions, unless the transaction is approved by the board of directors and the holders of at least <font style="white-space:nowrap">two-thirds</font> of the outstanding
voting stock of the corporation, Section&#160;203 prohibits significant business transactions such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger with, disposition of significant assets to or receipt of disproportionate financial benefits by the
interested stockholder, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other transaction that would increase the interested stockholder&#146;s proportionate ownership of any class
or series of our capital stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares held by the interested stockholder are not counted as outstanding when
calculating the <font style="white-space:nowrap">two-thirds</font> of the outstanding voting stock needed for approval. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-20- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prohibition against these transactions does not apply if: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the time that any stockholder became an interested stockholder, the board of directors approved either
the business combination or the transaction in which such stockholder acquired 15% or more of our outstanding voting stock, or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interested stockholder owns at least 85% of our outstanding voting stock as a result of a transaction in
which such stockholder acquired 15% or more of our outstanding voting stock. Shares held by persons who are both directors and officers or by some types of employee stock plans are not counted as outstanding when making this calculation.
</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Super-Majority Voting. </i>The DGCL provides generally that the affirmative vote of a majority of the shares
entitled to vote on any matter is required to amend a corporation&#146;s certificate of incorporation or <font style="white-space:nowrap">by-laws,</font> unless a corporation&#146;s certificate of incorporation or
<font style="white-space:nowrap">by-laws,</font> as the case may be, require a greater percentage. Our <font style="white-space:nowrap">by-laws</font> may be amended or repealed by a majority vote of our board of directors or the affirmative vote of
the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be
entitled to cast in any annual election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of incorporation described in this paragraph. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Directors&#146; Liability </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
certificate of incorporation limits the personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the DGCL. Our certificate of incorporation provides that no director will have personal liability to us or to our
stockholders for monetary damages for breach of fiduciary duty or other duty as a director. However, these provisions do not eliminate or limit the liability of any of our directors: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for any breach of their duty of loyalty to us or our stockholders; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for voting or assenting to unlawful payments of dividends or other distributions; or </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for any transaction from which the director derived an improper personal benefit. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act or failure to
act, or any cause of action, suit or claim that would accrue or arise prior to any amendment or repeal or addition of an inconsistent provision. If the DGCL is amended to provide for further limitations on the personal liability of directors of
corporations, then the personal liability of our directors will be further limited to the greatest extent permitted by the DGCL. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-21- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc201932_9"></a>DESCRIPTION OF WARRANTS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants to purchase common stock, preferred stock or debt securities. We may offer warrants separately or together with one or
more additional warrants, common stock, preferred stock or debt securities, or any combination of those securities in the form of units, as described in the applicable prospectus supplement. If we issue warrants as part of a unit, the accompanying
prospectus supplement will specify whether those warrants may be separated from the other securities in the unit prior to the expiration date of the warrants. The applicable prospectus supplement will also describe the following terms of any
warrants: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the specific designation and aggregate number of, and the offering price at which we will issue, the warrants;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currency units in which the offering price, if any, and the exercise price are payable;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will begin and the date on which that right will expire or,
if you may not continuously exercise the warrants throughout that period, the specific date or dates on which you may exercise the warrants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the warrants are to be sold separately or with other securities as parts of units; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the warrants will be issued in definitive or global form or in any combination of these forms, although,
in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any applicable material U.S. federal income tax consequences; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents,
transfer agents, registrars or other agents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any
securities exchange; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of any equity securities purchasable upon exercise of the warrants;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, aggregate principal amount, currency and terms of any debt securities that may be purchased upon
exercise of the warrants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the preferred stock with which the warrants are issued and the number
of warrants issued with each security; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date from and after which any warrants issued as part of a unit and the related debt
securities, preferred stock or common stock will be separately transferable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of common stock or preferred stock purchasable upon exercise of a warrant and the price at
which those shares may be purchased; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information with respect to book-entry procedures, if any; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anti-dilution provisions of, and other provisions for changes to or adjustment in the exercise price of, the
warrants, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any redemption or call provisions; and </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange or
exercise of the warrants. </p></td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-22- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc201932_10"></a>DESCRIPTION OF UNITS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units comprised of one or more of the other securities that may be offered under this prospectus, in any combination. The
following, together with the additional information we may include in the applicable prospectus supplement, summarizes the material terms and provisions of the units that we may offer under this prospectus. While the terms summarized below will
apply generally to any units we may offer, we will describe the particular terms of any series of units in more detail in the applicable prospectus supplement. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit
will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately at any time, or at any time
before a specified date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any applicable<b> </b>prospectus supplement will describe: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the material terms of the units and of the securities comprising the units, including whether and under what
circumstances those securities may be held or transferred separately; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any material provisions relating to the issuance, payment, settlement, transfer or exchange of the units or of
the securities comprising the units; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any material provisions of the governing unit agreement that differ from those described above.
</p></td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-23- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc201932_11"></a>FORMS OF SECURITIES </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each debt security, unit and warrant will be represented either by a certificate issued in definitive form to a particular investor or by one
or more global securities representing the entire issuance of securities. Unless the applicable prospectus supplement provides otherwise, certificated securities in definitive form and global securities will be issued in registered form. Definitive
securities name you or your nominee as the owner of the security, and in order to transfer or exchange these securities or to receive payments other than interest or other interim payments, you or your nominee must physically deliver the securities
to the trustee, registrar, paying agent or other agent, as applicable. Global securities name a depositary or its nominee as the owner of the debt securities, units or warrants represented by these global securities. The depositary maintains a
computerized system that will reflect each investor&#146;s beneficial ownership of the securities through an account maintained by the investor with its broker/dealer, bank, trust company or other representative, as we explain more fully below. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Global Securities </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt
securities, units and warrants in the form of one or more fully registered global securities that will be deposited with a depositary or its nominee identified in the applicable prospectus supplement and registered in the name of that depositary or
nominee. In those cases, one or more global securities will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal or face amount of the securities to be represented by global securities. Unless and
until it is exchanged in whole for securities in definitive registered form, a global security may not be transferred except as a whole by and among the depositary for the global security, the nominees of the depositary or any successors of the
depositary or those nominees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If not described below, any specific terms of the depositary arrangement with respect to any securities to
be represented by a global security will be described in the prospectus supplement relating to those securities. We anticipate that the following provisions will apply to all depositary arrangements. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ownership of beneficial interests in a global security will be limited to persons, called participants, that have accounts with the depositary
or persons that may hold interests through participants. Upon the issuance of a global security, the depositary will credit, on its book-entry registration and transfer system, the participants&#146; accounts with the respective principal or face
amounts of the securities beneficially owned by the participants. Any dealers, underwriters or agents participating in the distribution of the securities will designate the accounts to be credited. Ownership of beneficial interests in a global
security will be shown on, and the transfer of ownership interests will be effected only through, records maintained by the depositary, with respect to interests of participants, and on the records of participants, with respect to interests of
persons holding through participants. The laws of some states may require that some purchasers of securities take physical delivery of these securities in definitive form. These laws may impair your ability to own, transfer or pledge beneficial
interests in global securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as the depositary, or its nominee, is the registered owner of a global security, that depositary
or its nominee, as the case may be, will be considered the sole owner or holder of the securities represented by the global security for all purposes under the applicable indenture, warrant agreement or unit agreement. Except as described below,
owners of beneficial interests in a global security will not be entitled to have the securities represented by the global security registered in their names, will not receive or be entitled to receive physical delivery of the securities in
definitive form and will not be considered the owners or holders of the securities under the applicable indenture, unit agreement or warrant agreement. Accordingly, each person owning a beneficial interest in a global security must rely on the
procedures of the depositary for that global security and, if that person is not a participant, on the procedures of the participant through which the person owns its interest, to exercise any rights of a holder under the applicable indenture, unit
agreement or warrant agreement. We understand that under existing industry practices, if we request any action of holders or if an owner of a beneficial interest in a global security desires to give or take any action that a holder is entitled to
give or take </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-24- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the applicable indenture, unit agreement or warrant agreement, the depositary for the global security would authorize the participants holding the relevant beneficial interests to give or
take that action, and the participants would authorize beneficial owners owning through them to give or take that action or would otherwise act upon the instructions of beneficial owners holding through them. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Principal, premium, if any, and interest payments on debt securities, and any payments to holders with respect to warrants or units,
represented by a global security registered in the name of a depositary or its nominee will be made to the depositary or its nominee, as the case may be, as the registered owner of the global security. None of us, or any trustee, warrant agent, unit
agent or other agent of ours, or any agent of any trustee, warrant agent or unit agent will have any responsibility or liability for any aspect of the records relating to payments made on account of beneficial ownership interests in the global
security or for maintaining, supervising or reviewing any records relating to those beneficial ownership interests. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the
depositary for any of the securities represented by a global security, upon receipt of any payment to holders of principal, premium, interest or other distribution of underlying securities or other property on that registered global security, will
immediately credit participants&#146; accounts in amounts proportionate to their respective beneficial interests in that global security as shown on the records of the depositary. We also expect that payments by participants to owners of beneficial
interests in a global security held through participants will be governed by standing customer instructions and customary practices, as is now the case with the securities held for the accounts of customers or registered in &#147;street name,&#148;
and will be the responsibility of those participants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the depositary for any of the securities represented by a global security is at
any time unwilling or unable to continue as depositary or ceases to be a clearing agency registered under the Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by us within 90 days, we
will issue securities in definitive form in exchange for the global security that had been held by the depositary. Any securities issued in definitive form in exchange for a global security will be registered in the name or names that the depositary
gives to the relevant trustee, warrant agent, unit agent or other relevant agent of ours or theirs. It is expected that the depositary&#146;s instructions will be based upon directions received by the depositary from participants with respect to
ownership of beneficial interests in the global security that had been held by the depositary. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-25- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc201932_12"></a>PLAN OF DISTRIBUTION </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through underwriters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through dealers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to purchasers; or </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of these methods of sale. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may issue the securities as a dividend or distribution or in a subscription rights offering to our existing security holders. This prospectus
may be used in connection with any offering of our securities through any of these methods or other methods described in the applicable prospectus supplement. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may directly solicit offers to purchase securities, or agents may be designated to solicit such offers. We will, in the prospectus
supplement relating to such offering, name any agent that could be viewed as an underwriter under the Securities Act, and describe any commissions that we must pay. Any such agent will be acting on a best efforts basis for the period of its
appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of the securities may
be effected from time to time in one or more transactions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price, or prices, which may be changed from time to time; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each prospectus supplement will describe the method of distribution of the securities and any applicable restrictions. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect to the securities of a particular series will describe the terms of the offering of the securities,
including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name of the agent or any underwriters; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the public offering or purchase price and the proceeds we will receive from the sale of the securities;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts and commissions to be allowed or <font style="white-space:nowrap">re-allowed</font> or paid to the
agent or underwriters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all other items constituting underwriting compensation; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts and commissions to be allowed or <font style="white-space:nowrap">re-allowed</font> or paid to
dealers; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any exchanges on which the securities will be listed. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any underwriters or agents are utilized in the sale of the securities in respect of which this prospectus is delivered, we will enter into
an underwriting agreement or other agreement with them at the time of sale to them, and we will set forth in the prospectus supplement relating to such offering the names of the underwriters or agents and the terms of the related agreement with
them. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is utilized in the sale of the securities in respect of which this prospectus is delivered, we will sell such
securities to the dealer, as principal. The dealer may then resell such securities to the public at varying prices to be determined by such dealer at the time of resale. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-26- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer securities in a subscription rights offering to our existing security holders,
we may enter into a standby underwriting agreement with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter into a standby
underwriting arrangement, we may retain a dealer-manager to manage a subscription rights offering for us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Remarketing firms, agents,
underwriters, dealers and other persons may be entitled under agreements which they may enter into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, and may be customers of, engage in
transactions with or perform services for us in the ordinary course of business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so indicated in the applicable prospectus supplement,
we will authorize underwriters or other persons acting as our agents to solicit offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the
prospectus supplement. Each contract will be for an amount not less than, and the aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement.
Institutions with whom the contracts, when authorized, may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases
be subject to our approval. Delayed delivery contracts will not be subject to any conditions except that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase by an institution of the securities covered under that contract shall not at the time of delivery be
prohibited under the laws of the jurisdiction to which that institution is subject; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are also being sold to underwriters acting as principals for their own account, the
underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and other persons acting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts.
</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain agents, underwriters and dealers, and their associates and affiliates may be customers of, have borrowing
relationships with, engage in other transactions with, and/or perform services, including investment banking services, for us or one or more of our respective affiliates in the ordinary course of business. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the securities, any underwriters may engage in transactions that stabilize, maintain or otherwise
affect the price of the securities or any other securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may overallot in connection with the offering, creating a short position for their
own accounts. In addition, to cover overallotments or to stabilize the price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such other securities in the open market. Finally, in
any offering of the securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the offering if the syndicate repurchases
previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent market levels.
Any such underwriters are not required to engage in these activities and may end any of these activities at any time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Rule <font style="white-space:nowrap">15c6-1</font> of the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless the parties to any such trade expressly agree otherwise or the securities are sold by us to an
underwriter in a firm commitment underwritten offering. The applicable prospectus supplement may provide that the original issue date for your securities may be more than two scheduled business days after the trade date for your securities.
Accordingly, in such a case, if you wish to trade securities on any date prior to the second business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities initially are expected to
settle in more than two scheduled business days after the trade date for your securities, to make alternative settlement arrangements to prevent a failed settlement. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-27- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be new issues of securities and may have no established trading market.
The securities may or may not be listed on a national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In compliance with the guidelines of the Financial Industry Regulatory Authority, or FINRA, the aggregate maximum discount, commission or
agency fees or other items constituting underwriting compensation to be received by any FINRA member or independent broker-dealer will not exceed 8% of the proceeds from any offering pursuant to this prospectus and any applicable prospectus
supplement. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-28- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc201932_13"></a>LEGAL MATTERS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement indicates otherwise, the validity of the securities in respect of which this prospectus is being
delivered will be passed upon by Wilmer Cutler Pickering Hale and Dorr LLP, Boston, Massachusetts. </p> <p align="center" style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc201932_14"></a>EXPERTS
</b></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of AVEO Pharmaceuticals, Inc. appearing in AVEO Pharmaceuticals, Inc.&#146;s Annual Report
(Form <font style="white-space:nowrap">10-K)</font> for the year ended December&#160;31, 2019 and the effectiveness of AVEO Pharmaceuticals, Inc.&#146;s internal control over financial reporting as of December&#160;31, 2019 have been audited by
Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, as set forth in its reports thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about AVEO Pharmaceuticals, Inc.&#146;s
ability to continue as a going concern as described in Note 1 to the consolidated financial statements), and incorporated herein by reference. Such financial statements have been incorporated herein by reference in reliance upon such reports given
on the authority of such firm as experts in accounting and auditing. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-29- </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&#160;</p>
<p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<p align="center" style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="https://www.sec.gov/Archives/edgar/data/0001325879/000119312520289207/g201932g11k45.jpg"/>
</p> <p align="center" style="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><b>$300,000,000 </b></p>
<p align="center" style="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Common Stock </b></p> <p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Preferred
Stock </b></p> <p align="center" style="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Debt Securities </b></p>
<p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Warrants </b></p> <p align="center" style="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Units </b></p>
<p style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><b>PROSPECTUS </b></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2020 </b></p>
<p style="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p>
<p style="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&#160;</p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><font color="#ff4338"><b>The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction
where the offer or sale is not permitted. </b></font></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><font color="#ff4338"><b>Subject to completion, dated November&#160;9, 2020 </b></font></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman"><b>PROSPECTUS </b></p>
<p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><b>Up to $31,794,031 </b></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p align="center" style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="https://www.sec.gov/Archives/edgar/data/0001325879/000119312520289207/g201932g11k45.jpg"/>
</p> <p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Common Stock </b></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We have entered
into a sales agreement, or the Sales Agreement, with Leerink Partners LLC (now known as SVB Leerink LLC), or SVB Leerink, dated February&#160;16, 2018 and amended on November&#160;9, 2020, relating to the sale of shares of our common stock, par
value $0.001 per share, offered by this prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $50,000,000 from time to time through SVB Leerink,
acting as our agent. In this prospectus, we refer to a prior sales agreement prospectus supplement dated February&#160;16, 2018 as the prior prospectus supplement. The prior prospectus supplement provided for sales of shares of our common stock
having an aggregate offering price of up to $50,000,000. As of the date of this prospectus, we had issued and sold shares of our common stock pursuant to the Sales Agreement and the prior prospectus supplement for which we had received gross
proceeds of approximately $18,205,969 and $31,794,031 remained unsold. The common stock remaining available to be sold under the prior prospectus supplement as of the date of this prospectus will no longer be offered and sold under the prior
prospectus supplement, but will instead be offered and sold under this prospectus. Accordingly, this prospectus covers the offer and sale of up to $31,794,031 of our common stock that may be sold under the Sales Agreement as of the date of this
prospectus. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market under the symbol &#147;AVEO&#148;. On November&#160;6, 2020, the last
reported sale price of our common stock on the Nasdaq Capital Market was $5.66 per share. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We are a smaller reporting company as defined
in Rule <font style="white-space:nowrap">12b-2</font> promulgated under the Securities Exchange Act of 1934, as amended. As such, we have elected to rely on certain reduced public company disclosure requirements. See &#147;Prospectus Summary &#151;
Implications of Being a Smaller Reporting Company.&#148; </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Sales of our common stock, if any, under this prospectus may be made in sales
deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. SVB Leerink is not required to sell any specific number or dollar amount of shares of
our common stock but will act as our sales agent on a best efforts basis and use commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us consistent with its normal trading and sales
practices, on mutually agreed terms between SVB Leerink and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">The compensation payable to SVB Leerink for sales of common stock sold pursuant to the Sales Agreement will be an amount up to 3.0% of the
gross proceeds of any shares of common stock sold under the Sales Agreement. See &#147;Plan of Distribution&#148; beginning on page <font style="white-space:nowrap">SA-16</font> for additional information regarding the compensation to be paid to SVB
Leerink. In connection with the sale of the common stock on our behalf, SVB Leerink will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act, and the compensation paid to SVB Leerink will be deemed to be underwriting
commissions or discounts. We have also agreed in the Sales Agreement to provide indemnification and contribution to SVB Leerink with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of
1934, as amended. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:11.5pt; font-family:Times New Roman"><b>Investing in our common stock involves significant risks. See &#147;<a href="#stoc201932_4">Risk Factors</a>&#148; beginning on page <font style="white-space:nowrap">SA-6</font> of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities. </b></p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </b></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center> <p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><b>SVB Leerink
</b></p> <p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman"><b>The date of this prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2020 </b></p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>TABLE OF CONTENTS </b></p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr>
<td width="93%"></td>
<td valign="bottom" width="1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#stoc201932_1">ABOUT THIS PROSPECTUS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">&#160;</td>
<td align="right" nowrap="" valign="bottom"><font style="white-space:nowrap">SA-1</font></td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#stoc201932_2">PROSPECTUS SUMMARY</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">&#160;</td>
<td align="right" nowrap="" valign="bottom"><font style="white-space:nowrap">SA-3</font></td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#stoc201932_3">THE OFFERING</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">&#160;</td>
<td align="right" nowrap="" valign="bottom"><font style="white-space:nowrap">SA-5</font></td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#stoc201932_4">RISK FACTORS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">&#160;</td>
<td align="right" nowrap="" valign="bottom"><font style="white-space:nowrap">SA-6</font></td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#stoc201932_5">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">&#160;</td>
<td align="right" nowrap="" valign="bottom"><font style="white-space:nowrap">SA-8</font></td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#stoc201932_6">USE OF PROCEEDS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">&#160;</td>
<td align="right" nowrap="" valign="bottom"><font style="white-space:nowrap">SA-10</font></td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#stoc201932_7">DIVIDEND POLICY</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">&#160;</td>
<td align="right" nowrap="" valign="bottom"><font style="white-space:nowrap">SA-11</font></td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#stoc201932_8">DILUTION</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">&#160;</td>
<td align="right" nowrap="" valign="bottom"><font style="white-space:nowrap">SA-12</font></td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#stoc201932_9">DESCRIPTION OF COMMON STOCK</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">&#160;</td>
<td align="right" nowrap="" valign="bottom"><font style="white-space:nowrap">SA-13</font></td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#stoc201932_10">PLAN OF DISTRIBUTION</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">&#160;</td>
<td align="right" nowrap="" valign="bottom"><font style="white-space:nowrap">SA-16</font></td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#stoc201932_11">LEGAL MATTERS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">&#160;</td>
<td align="right" nowrap="" valign="bottom"><font style="white-space:nowrap">SA-18</font></td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#stoc201932_12">EXPERTS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">&#160;</td>
<td align="right" nowrap="" valign="bottom"><font style="white-space:nowrap">SA-18</font></td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#stoc201932_13">WHERE YOU CAN FIND MORE INFORMATION</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">&#160;</td>
<td align="right" nowrap="" valign="bottom"><font style="white-space:nowrap">SA-19</font></td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#stoc201932_14">INCORPORATION BY REFERENCE</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">&#160;</td>
<td align="right" nowrap="" valign="bottom"><font style="white-space:nowrap">SA-19</font></td>
<td nowrap="" valign="bottom">&#160;</td></tr>
</table>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="stoc201932_1"></a>ABOUT THIS PROSPECTUS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, which we refer to as the
&#147;SEC,&#148; utilizing a &#147;shelf&#148; registration process. Under this shelf registration process, we may from time to time sell shares of our common stock having an aggregate offering price of up to $300,000,000. Under this prospectus, we
may from time to time sell shares of our common stock having an aggregate offering price of up to $31,794,031, at prices and on terms to be determined by market conditions at the time of the offering. The $31,794,031 of shares of our common stock
that may be sold under this prospectus are included in the $300,000,000 of shares of common stock that may be sold under the registration statement. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information that we have included or incorporated by reference in this prospectus and any related free writing
prospectus that we have authorized for use in connection with this offering. Neither we nor SVB Leerink LLC, or SVB Leerink, has authorized any dealer, salesman or other person to give any information or to make any representation other than those
contained or incorporated by reference in this prospectus or any related free writing prospectus that we have authorized for use in connection with this offering. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by
reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the
current state of our affairs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any related free writing prospectus do not constitute an offer to sell, or the
solicitation of an offer to buy, the securities offered by this prospectus in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. You should assume that the
information contained in this prospectus, and the documents incorporated by reference herein and in any free writing prospectus that we have authorized for use in connection with this offering is accurate only as of the date of those respective
documents, even though this prospectus or any related free writing prospectus may be delivered, or securities sold, on a later date. Our business, financial condition, results of operations and prospects may have changed materially since those
dates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, including the information incorporated by reference herein, and any related free writing
prospectus that we have authorized for use in connection with this offering. You should also read and consider the information in the documents we have referred you to in the sections of this prospectus entitled &#147;Where You Can Find More
Information&#148; and &#147;Information Incorporated by Reference.&#148; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains or incorporates by reference summaries
of certain provisions contained in some of the documents described herein, but all such summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been or will be filed or have been or
will be incorporated by reference as exhibits to the registration statement of which this prospectus forms a part, and you may obtain copies of those documents as described in this prospectus under the heading &#147;Where You Can Find More
Information.&#148; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than in the United States, no action has been taken by us or SVB Leerink that would permit a public offering of
the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering
material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that
jurisdiction. Neither we nor SVB Leerink have </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-1 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authorized anyone to provide any information or to make any representations other than those contained or incorporated by reference in this prospectus or in any free writing prospectus that we
have authorized for use in connection with this offering. We and SVB Leerink take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Persons into whose possession this
prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-2 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="stoc201932_2"></a>PROSPECTUS SUMMARY </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>This summary highlights selected information contained elsewhere in, or incorporated by reference into, this prospectus. Because it is only
a summary, it does not contain all of the information that you should consider before investing in our common stock, and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in
this prospectus, any free writing prospectus that we have authorized for use in connection with this offering and the documents incorporated by reference in this prospectus. You should read all such documents carefully, and you should pay special
attention to the information contained under the caption entitled &#147;Risk Factors&#148; in this prospectus, in our Annual Reports <font style="white-space:nowrap">on&#160;Form&#160;10-K,&#160;in</font> any subsequent Quarterly Reports <font style="white-space:nowrap">on&#160;Form&#160;10-Q&#160;and</font> in our other reports filed from time to time with the SEC, which are incorporated by reference into this prospectus, before deciding to buy shares of our common stock. Unless the
context requires otherwise, references in this prospectus to &#147;AVEO,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to AVEO Pharmaceuticals,&#160;Inc. and our subsidiaries. </i></p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Company Overview </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. Our strategy is to focus our resources toward development and commercialization of our product candidates in North America
while leveraging partnerships to support development and commercialization in other geographies. Our lead candidate is tivozanib (FOTIVDA<sup style="font-size:85%; vertical-align:top">&#174;</sup>), a vascular endothelial growth factor receptor
tyrosine kinase inhibitor. FOTIVDA is approved through our development partner EUSA Pharma (UK) Limited in the European Union, the United Kingdom, Norway, New Zealand and Iceland for the first-line treatment of adult patients with advanced renal
cell carcinoma. We are working to develop and potentially commercialize tivozanib in the U.S. as a treatment for renal cell carcinoma. We are also studying tivozanib in combination with immune checkpoint inhibitors for the treatment of renal cell
carcinoma and hepatocellular carcinoma in phase 2 clinical trials. We have previously reported promising early clinical data on ficlatuzumab, a hepatocyte growth factor inhibitory antibody, in squamous cell carcinoma of the head and neck, acute
myeloid leukemia and pancreatic cancer. Our earlier stage pipeline under development includes <font style="white-space:nowrap">AV-203,</font> an anti-ErbB3 monoclonal antibody, as a potential oncology treatment;
<font style="white-space:nowrap">AV-380,</font> a humanized IgG1 inhibitory monoclonal antibody targeting growth differentiation factor 15, a divergent member of the <font style="white-space:nowrap">TGF-&#223;</font> family, for the potential
treatment of cancer cachexia; and <font style="white-space:nowrap">AV-353,</font> which targets the Notch 3 pathway, as a potential oncology treatment. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Company Information </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated
in Delaware on October&#160;19, 2001 as GenPath Pharmaceuticals, Inc. and changed our name to AVEO Pharmaceuticals, Inc. on March&#160;1, 2005. Our principal executive offices are located at 30 Winter Street, Boston, Massachusetts 02108, and our
telephone number is (857) <font style="white-space:nowrap">400-0101.</font> Our website address is www.aveooncology.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included
our website address in this prospectus solely as an inactive textual reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trademarks, trade names and service marks appearing
in this prospectus are the property of their respective owners. </p>
</div><br clear="All"/></div><br clear="All"/>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-3 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Implications of Being a Smaller Reporting Company </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a &#147;smaller reporting company&#148; meaning that the market value of our stock held by
<font style="white-space:nowrap">non-affiliates</font> is less than $700&#160;million and our annual revenue was less than $100&#160;million during our most recently completed fiscal year. We may continue to be a smaller reporting company if either
(i)&#160;the market value of our stock held by <font style="white-space:nowrap">non-affiliates</font> is less than $250&#160;million or (ii)&#160;our annual revenue was less than $100&#160;million during the most recently completed fiscal year and
the market value of our stock held by <font style="white-space:nowrap">non-affiliates</font> is less than $700&#160;million. For so long as we remain a smaller reporting company, we are permitted and intend to rely on exemptions from certain
disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies. </p>
</div><br clear="All"/></div><br clear="All"/>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-4 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="stoc201932_3"></a>THE OFFERING </b></p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr valign="TOP">
<td width="38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><b>Common Stock Offered by Us </b></p></td>
<td>Shares of our common stock having an aggregate offering price of up to $31,794,031. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr valign="TOP">
<td width="38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><b>Common Stock to be Outstanding After this Offering </b></p></td>
<td>Up to 31,425,634 shares, assuming a sales price of $5.66 per share, which was the closing price of our common stock on the Nasdaq Capital Market on November&#160;6, 2020. The actual number of shares issued will vary depending on the sales price
under this offering. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr valign="TOP">
<td width="38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><b>Manner of Offering </b></p></td>
<td>&#147;At the market offering&#148; that may be made from time to time through our sales agent, SVB Leerink. See &#147;Plan of Distribution&#148; on page <font style="white-space:nowrap">SA-16.</font> </td></tr></table>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr valign="TOP">
<td width="38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><b>Use of Proceeds </b></p></td>
<td>We intend to use the net proceeds from this offering, if any, for working capital and general corporate purposes, including research and development expenses, general and administrative expenses, commercialization expenses and potential business
development opportunities. See &#147;Use of Proceeds.&#148; </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr valign="TOP">
<td width="38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><b>Risk Factors </b></p></td>
<td>Investing in our common stock involves a high degree of risk. You should read the &#147;Risk Factors&#148; section of this prospectus beginning <font style="white-space:nowrap">on&#160;page&#160;SA-6&#160;as</font> well as those risk factors
that are incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in our common stock. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr valign="TOP">
<td width="38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><b>Nasdaq Capital Market symbol </b></p></td>
<td>&#147;AVEO&#148; </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 25,808,315
shares of our common stock outstanding as of September&#160;30, 2020. The number of shares of our common stock to be outstanding as used throughout this prospectus supplement, unless otherwise indicated, excludes: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,690,695 shares of common stock issuable upon exercise of stock options outstanding as of September&#160;30,
2020 at a weighted-average exercise price of $12.86 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,683,933 shares of common stock issuable upon exercise of warrants outstanding as of September&#160;30, 2020,
and issued in connection with a private placement financing in May 2016, which we refer to as the PIPE Warrants, at an exercise price of $10.00 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,500,000 shares of common stock issuable upon exercise of warrants outstanding as of September&#160;30, 2020,
and issued in connection with a public offering in April 2019, which we refer to as the Offering Warrants, at an exercise price of $12.50 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,670,211 shares of common stock reserved as of September&#160;30, 2020 for future issuance under our 2019 Equity
Incentive Plan; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27,131 shares of common stock reserved as of September&#160;30, 2020 for future issuance under our 2010 employee
stock purchase plan. </p></td></tr></table>
</div><br clear="All"/></div><br clear="All"/>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-5 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="stoc201932_4"></a>RISK FACTORS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should
carefully consider the risks described below and those discussed under the caption entitled &#147;Risk Factors&#148; in our Annual Report on <font style="white-space:nowrap">Form&#160;10-K</font> for the year ended December&#160;31, 2019 and any
subsequent Quarterly Reports on <font style="white-space:nowrap">Form&#160;10-Q,</font> which are incorporated by reference in this prospectus, together with other information in this prospectus, the information and documents incorporated by
reference herein, and in any free writing prospectus that we have authorized for use in connection with this offering. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously
harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. </i></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Risks Related to
this Offering </b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><i>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </i></b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that
do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses, and these financial losses could have a material adverse effect on
our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><i>It is not possible to predict the aggregate proceeds resulting from sales made under the Sales Agreement. </i></b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain limitations in the sales agreement, or the Sales Agreement, with SVB Leerink, dated February&#160;16, 2018 and amended on
November&#160;9, 2020, and compliance with applicable law, we have the discretion to deliver a placement notice to SVB Leerink at any time throughout the term of the Sales Agreement. The number of shares that are sold through SVB Leerink after
delivering a placement notice will fluctuate based on a number of factors, including the market price of our common stock during the sales period, any limits we may set with SVB Leerink in any applicable placement notice and the demand for our
common stock. Because the price per share of each share sold pursuant to the Sales Agreement will fluctuate over time, it is not currently possible to predict the aggregate proceeds to be raised in connection with sales under the Sales Agreement.
</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><i>The common stock offered hereby may be sold in &#147;at the market offerings,&#148; and investors who buy shares at different times will likely pay
different prices. </i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors who purchase shares in this offering at different times will likely pay different prices, and
accordingly may experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices and number of shares sold in this offering. In addition,
subject to the final determination by our board of directors or any restrictions we may place in any applicable placement notice, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a decline
in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><i>If you purchase our
common stock in this offering, you may incur immediate and substantial dilution in the book value of your shares. </i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering
price per share of common stock in this offering may exceed the net tangible book value per share of our common stock outstanding prior to this offering. Therefore, if you purchase common stock in this offering, you may pay a price per share that
exceeds our as adjusted net tangible book value per share of common stock. Assuming that an aggregate of 5,617,319 shares of our common stock are sold at an assumed offering </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-6 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
price of $5.66 per share, the last reported sale price of our common stock on the Nasdaq Capital Market on November&#160;6, 2020, for aggregate gross proceeds of $31,794,031, and after deducting
estimated commissions and estimated offering expenses payable by us, you would experience immediate dilution of $3.41 per share, representing the difference between our as adjusted net tangible book value per share as of September&#160;30, 2020,
immediately after giving effect to this offering, and the assumed offering price. To the extent outstanding options or warrants are exercised, you will experience further dilution. See the section titled &#147;Dilution&#148; below for a more
detailed illustration of the dilution you would incur if you participate in this offering. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><i>If you purchase shares of common stock in this offering,
you may also experience future dilution as a result of future equity offerings. </i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To raise additional capital, we may in the future
offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other
offering at a price per share that is less than the price per share paid by any investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at
which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by any investors in this offering. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><i>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole
source of gain. </i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our
future earnings, if any, to finance the growth and development of our business. In addition, the terms of our current debt agreement precludes us, and any future debt agreements that we may enter into may preclude us, from paying dividends without
the lenders&#146; consent or at all. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-7 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="stoc201932_5"></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents we incorporate by reference herein include forward-looking statements within the meaning of Section&#160;27A
of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. Any statement contained in this prospectus or in the documents we incorporate by reference herein other than a statement of
historical fact, may be a forward-looking statement, including statements regarding our and our collaborators&#146; future discovery, development and commercialization efforts, our strategy, future operations, future financial position, future
revenue, projected costs, prospects, plans and objectives of management. In some cases, you can identify forward-looking statements by such terms as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148;
&#147;expect,&#148; &#147;forecast,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would&#148; or other words that convey
uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements may include, but are not limited to, statements about: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of future clinical trials, and our development programs;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to develop and commercialize our product candidates; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to secure new collaborations, maintain existing collaborations or obtain additional funding;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, strategic plans for our business, product candidates and technology;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance and clinical utility of our products; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments and projections relating to our competitors and our industry; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of the period in which we anticipate that existing cash, cash equivalents and investments will
enable us to fund our current and planned operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue as a going concern; and </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intended use of proceeds from this offering. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors,
including risks relating to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability, and the ability of our licensees, to demonstrate to the satisfaction of applicable regulatory
agencies the safety, efficacy and clinically meaningful benefit of our product candidates, including as it relates to the <font style="white-space:nowrap">TIVO-3</font> trial and tivozanib; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impacts of the <font style="white-space:nowrap">COVID-19</font> pandemic on our clinical trials, business and
operations, including our efforts to obtain regulatory approval of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize tivozanib in the United States, if approved by the FDA; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise the substantial additional funds required to achieve our goals, including those goals
pertaining to the development and commercialization of tivozanib, which could be adversely affected by the impact of the <font style="white-space:nowrap">COVID-19</font> pandemic on the global financial markets; </p></td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-8 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into and maintain our third-party collaboration agreements and our ability, and the ability
of our strategic partners, to achieve development and commercialization objectives under these arrangements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and costs of any product candidate seeking and obtaining regulatory approval; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability, and the ability of our collaborators, to successfully enroll and complete clinical trials;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain compliance with regulatory requirements applicable to our product candidates;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain adequate protection for intellectual property rights relating to our product
candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully implement our strategic plans; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unplanned capital requirements; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse general economic and industry conditions; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitive factors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue as a going concern; and </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">those risks discussed (i)&#160;under the heading &#147;Risk Factors&#148; beginning on page <font style="white-space:nowrap">SA-6</font> of this prospectus, (ii)&#160;in the section titled &#147;Risk Factors&#148; in our Annual Report on Form <font style="white-space:nowrap">10-K</font> for the year ended December&#160;31, 2019, and our
Quarterly Reports on Form <font style="white-space:nowrap">10-Q</font> for the quarters ended March&#160;31, 2020, June&#160;30, 2020 and September&#160;30, 2020, each as filed with the U.S. Securities and Exchange Commission, or the SEC, and
(iii)&#160;in other filings we make with the SEC from time to time. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If one or more of these factors materialize, or if
any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should consider these factors and the other cautionary statements made in this prospectus and the documents we incorporate by reference
herein as being applicable to all related forward-looking statements wherever they appear in this prospectus or the documents incorporated by reference. While we may elect to update forward-looking statements wherever they appear in this prospectus
or the documents incorporated by reference herein, we do not assume, and specifically disclaim, any obligation to do so, whether as a result of new information, future events or otherwise, unless required by law. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated by reference herein include statistical and other industry and market data that we obtained
from industry publications and research, surveys and studies conducted by third parties. All of the market data used in this prospectus and the information incorporated by reference herein involves a number of assumptions and limitations, and you
are cautioned not to give undue weight to such data. We believe that the information from these industry publications, surveys and studies is reliable. The industry in which we operate is subject to a high degree of uncertainty and risk due to a
variety of important factors, including those described under the heading &#147;Risk Factors&#148; in the section titled &#147;Risk Factors&#148; in our Annual Report on Form <font style="white-space:nowrap">10-K</font> for the year ended
December&#160;31, 2019 and our Quarterly Reports on Form <font style="white-space:nowrap">10-Q</font> for the quarters ended March&#160;31, 2020, June&#160;30, 2020 and September&#160;30, 2020. These and other factors could cause results to differ
materially from those expressed in the estimates made by the independent parties and by us. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-9 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="stoc201932_6"></a>USE OF PROCEEDS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $31,794,031 from time to time. Because there is no
minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions to SVB Leerink and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell
any shares under the Sales Agreement as a source of financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in any free writing prospectus that we may authorize
to be provided to you, we currently intend to use the net proceeds from this offering, if any, for working capital and general corporate purposes, including research and development expenses, general and administrative expenses, commercialization
expenses and potential business development opportunities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts and timing of our use of the net proceeds from the sale of
securities in this offering will depend on a number of factors, such as the timing and progress of our and our strategic partners&#146; clinical trials of our product candidates and our development efforts, any additional collaborations that we may
enter into with third parties for our product candidates, technological advances and the competitive environment for our product candidates. As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net
proceeds to us from this offering. Accordingly, our management will have broad discretion in the timing and application of these proceeds. Pending application of the net proceeds as described above, we intend to temporarily invest the proceeds in
short-term, interest-bearing instruments. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-10 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="stoc201932_7"></a>DIVIDEND POLICY </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our common stock and our ability to pay cash dividends is currently prohibited by the
terms of our debt financing arrangements with Hercules Funding III, LLC and Hercules Capital, Inc. We currently intend to retain earnings, if any, for use in our business and do not anticipate paying cash dividends on our common stock in the
foreseeable future. Payment of future dividends, if any, on our common stock will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, anticipated cash needs,
and plans for expansion. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-11 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="stoc201932_8"></a>DILUTION </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the price per share you pay in this offering and the as adjusted net tangible book value per share of our common stock immediately after giving effect to this offering. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value as of September&#160;30, 2020 was approximately $40.2&#160;million, or $1.56 per share of our common
stock. Our historical net tangible book value is the amount of our total tangible assets less our total liabilities. Historical net tangible book value per share represents historical net tangible book value divided by the 25,808,315 shares of our
common stock outstanding as of September&#160;30, 2020. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the assumed sale by us of shares of our common stock in
the aggregate amount of $31,794,031 at an assumed offering price of $5.66 per share, which was the last sale price of our common stock on November&#160;6, 2020 as reported on the Nasdaq Capital Market, less the estimated commissions and estimated
offering expenses payable by us, our as adjusted net tangible book value at September&#160;30, 2020 would have been $70.8&#160;million, or $2.25 per share. This represents an immediate increase in as adjusted net tangible book value of $0.69 per
share to existing stockholders and an immediate dilution of $3.41 per share to investors in this offering. The following table illustrates this per share dilution. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr>
<td width="88%"></td>
<td valign="bottom" width="2%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr bgcolor="#cceeff" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">$</td>
<td align="right" valign="bottom">5.66</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of September&#160;30, 2020</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">$</td>
<td align="right" valign="bottom">1.56</td>
<td nowrap="" valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr>
<tr bgcolor="#cceeff" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to new investors purchasing shares in this offering</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">$</td>
<td align="right" valign="bottom">0.69</td>
<td nowrap="" valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr>
<tr style="font-size:1px; ">
<td valign="bottom"></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share as of September&#160;30, 2020 after giving effect to
this offering</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">$</td>
<td align="right" valign="bottom">2.25</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1px; ">
<td valign="bottom"></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr bgcolor="#cceeff" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors purchasing shares in this offering</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">$</td>
<td align="right" valign="bottom">3.41</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1px; ">
<td valign="bottom"></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The as adjusted information is illustrative only and will adjust based on the actual price to the public, the
actual number of shares sold and other terms of the offering determined at the time shares of our common stock are sold pursuant to this prospectus. The shares sold in this offering, if any, will be sold from time to time at various prices. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for
our current or future operating plans. To the extent that additional capital is raised through the sale of equity or securities convertible into common stock, the issuance of these securities could result in further dilution to our stockholders.
</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above discussion and table are based on 25,808,315 shares of our common stock issued and outstanding as of September&#160;30, 2020
and excludes the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,690,695 shares of common stock issuable upon exercise of stock options outstanding as of September&#160;30,
2020 at a weighted-average exercise price of $12.86 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,683,933 shares of common stock issuable upon exercise of the PIPE Warrants outstanding as of September&#160;30,
2020, at an exercise price of $10.00 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,500,000 shares of common stock issuable upon exercise of the Offering Warrants outstanding as of
September&#160;30, 2020, at an exercise price of $12.50 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,670,211 shares of common stock reserved as of September&#160;30, 2020 for future issuance under our 2019 Equity
Incentive Plan; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27,131 shares of common stock reserved as of September&#160;30, 2020 for future issuance under our 2010 employee
stock purchase plan. </p></td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-12 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="stoc201932_9"></a>DESCRIPTION OF COMMON STOCK </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our common stock is intended as a summary only and therefore is not a complete description of our common stock.
This description is based upon, and is qualified by reference to, our restated certificate of incorporation, as amended, or our certificate of incorporation, our second amended and restated <font style="white-space:nowrap">by-laws,</font> or our <font style="white-space:nowrap">by-laws,</font> and applicable provisions of Delaware corporate law, or the DGCL. You should read our certificate of incorporation, certificate of amendment to our certificate of incorporation and <font style="white-space:nowrap">by-laws,</font> which are filed as exhibits to the registration statement of which this prospectus forms a part, for the provisions that are important to you. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized common stock consists of 50,000,000 shares of common stock. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Annual Meeting. </i>Annual meetings of our stockholders are held on the date designated in accordance with our <font style="white-space:nowrap">by-laws.</font> Written notice must be mailed to each stockholder entitled to vote not less than ten nor more than 60 days before the date of the meeting. The presence in person or by proxy of the holders of record of a
majority in voting power of our issued and outstanding shares entitled to vote at such meeting constitutes a quorum for the transaction of business at meetings of the stockholders. Special meetings of the stockholders, unless otherwise prescribed by
statute or by our certificate of incorporation, may be called for any purpose or purposes, by the chairman of our board of directors, our board of directors, or our chief executive officer. Except as may be otherwise provided by applicable law, our
certificate of incorporation or our <font style="white-space:nowrap">by-laws,</font> all elections, other than elections of directors, and all other questions shall be decided by the affirmative vote of the holders of a majority in voting power of
the shares of our stock which are present in person or by proxy and voting affirmatively or negatively on such matter. Except as may be provided by applicable law, our certificate of incorporation or our
<font style="white-space:nowrap">by-laws,</font> each director shall be elected by the vote of the plurality of the votes cast by the stockholders entitled to vote with respect to that director&#146;s election at any meeting for the election of
directors at which a quorum is present. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Voting Rights</i>. Each holder of common stock is entitled to one vote for each share held of
record on all matters to be voted upon by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Dividends</i>. Subject to the rights, powers and preferences of any
outstanding preferred stock, and except as provided by law or in our certificate of incorporation, dividends may be declared and paid or set aside for payment on the common stock out of legally available assets or funds when and as declared by the
board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Liquidation, Dissolution and Winding Up</i>. Subject to the rights, powers and preferences of any outstanding
preferred stock, in the event of our liquidation, dissolution or winding up, our net assets will be distributed pro rata to the holders of our common stock. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Other Rights</i>. Holders of the common stock have no right to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convert the stock into any other security; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have the stock redeemed; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase additional stock; or </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain their proportionate ownership interest. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The common stock does not have cumulative voting rights. Holders of shares of the common stock are not required to make additional capital
contributions. Outstanding shares of common stock are <font style="white-space:nowrap">non-assessable.</font> Holders of shares of the common stock are not, and will not be, subject to any liability as stockholders. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-13 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Transfer Agent and Registrar</i>. Computershare Trust Company, N.A. is transfer agent and
registrar for the common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Capital Market under the symbol &#147;AVEO&#148;. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Effects of Authorized by Unissued Stock </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Authorized but unissued shares of our common stock and preferred stock are available for future issuance without shareholder approval, subject
to any limitations imposed by the listing standards of the Nasdaq Capital Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefits. The existence of authorized but unissued and
unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. In addition, if we issue preferred stock, the issuance could
adversely affect the voting power of holders of common stock and the likelihood that such holder will receive dividend payments and payments upon liquidation. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Provisions of Our Certificate of Incorporation and <font style="white-space:nowrap">By-laws</font> and Delaware Law That May Have Anti-Takeover Effects
</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Board of Directors</i>. We do not have a classified board of directors. All of our directors are elected annually. The number of
directors comprising our board of directors is fixed from time to time by the board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Removal of Directors by
Stockholders</i>. Members of our board of directors may be removed from office at any time with or without cause by the affirmative vote of the holders of a majority of the outstanding shares entitled to vote at an election of directors. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Stockholder Nomination of Directors</i>. Our <font style="white-space:nowrap">by-laws</font> provide that a stockholder must notify us in
writing of any stockholder nomination of a director not earlier than the close of business on the 120<sup style="font-size:85%; vertical-align:top">th</sup> day, and not later than the close of business on the 90<sup style="font-size:85%; vertical-align:top">th</sup> day prior to the first anniversary of the preceding year&#146;s annual meeting; provided, that, in the case of the annual meeting of stockholders, if the date of the annual meeting is more than 20
days before or more than 60 days after such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120<sup style="font-size:85%; vertical-align:top">th</sup> day prior to the date
of such annual meeting and not later than the close of business on the later of (x)&#160;the 90<sup style="font-size:85%; vertical-align:top">th</sup> day prior to such annual meeting and (y)&#160;the
10<sup style="font-size:85%; vertical-align:top">th</sup> day following the day on which public announcement of the date of such annual meeting is first made by us. Our <font style="white-space:nowrap">by-laws</font> also provide that, subject to
certain limitations, if a stockholder (or a qualified representative of the stockholder) does not appear at a meeting of stockholders to present a nomination, such nomination shall be disregarded, notwithstanding that proxies in respect of such vote
may have been received by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>No Action By Written Consent</i>. Our certificate of incorporation and our <font style="white-space:nowrap">by-laws</font> provide that our stockholders may not act by written consent and may only act at duly called meetings of stockholders. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Delaware Business Combination Statute.</i> Section&#160;203 of the General Corporation Law of the State of Delaware, which we refer to as
the DGCL, is applicable to us. Section&#160;203 of the DGCL restricts some types of transactions and business combinations between a corporation and a 15% stockholder. A 15% stockholder is generally considered by Section&#160;203 to be a person
owning 15% or more of the corporation&#146;s outstanding voting stock. Section&#160;203 refers to a 15% stockholder as an &#147;interested stockholder.&#148; Section&#160;203 restricts these transactions for a period of three years from the date the
stockholder acquires 15% or more of our outstanding voting stock. With some exceptions, unless the transaction is approved by the board of directors and the holders of at least <font style="white-space:nowrap">two-thirds</font> of the outstanding
voting stock of the corporation, Section&#160;203 prohibits significant business transactions such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger with, disposition of significant assets to or receipt of disproportionate financial benefits by the
interested stockholder, and </p></td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-14 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other transaction that would increase the interested stockholder&#146;s proportionate ownership of any class
or series of our capital stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares held by the interested stockholder are not counted as outstanding when
calculating the <font style="white-space:nowrap">two-thirds</font> of the outstanding voting stock needed for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prohibition
against these transactions does not apply if: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the time that any stockholder became an interested stockholder, the board of directors approved either
the business combination or the transaction in which such stockholder acquired 15% or more of our outstanding voting stock, or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interested stockholder owns at least 85% of our outstanding voting stock as a result of a transaction in
which such stockholder acquired 15% or more of our outstanding voting stock. Shares held by persons who are both directors and officers or by some types of employee stock plans are not counted as outstanding when making this calculation.
</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Super-Majority Voting. </i>The DGCL provides generally that the affirmative vote of a majority of the shares
entitled to vote on any matter is required to amend a corporation&#146;s certificate of incorporation or <font style="white-space:nowrap">by-laws,</font> unless a corporation&#146;s certificate of incorporation or
<font style="white-space:nowrap">by-laws,</font> as the case may be, require a greater percentage. Our <font style="white-space:nowrap">by-laws</font> may be amended or repealed by a majority vote of our board of directors or the affirmative vote of
the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be
entitled to cast in any annual election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of incorporation described in this paragraph. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Directors&#146; Liability </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
certificate of incorporation limits the personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the DGCL. Our certificate of incorporation provides that no director will have personal liability to us or to our
stockholders for monetary damages for breach of fiduciary duty or other duty as a director. However, these provisions do not eliminate or limit the liability of any of our directors: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for any breach of their duty of loyalty to us or our stockholders; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for voting or assenting to unlawful payments of dividends or other distributions; or </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for any transaction from which the director derived an improper personal benefit. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act or failure to
act, or any cause of action, suit or claim that would accrue or arise prior to any amendment or repeal or addition of an inconsistent provision. If the DGCL is amended to provide for further limitations on the personal liability of directors of
corporations, then the personal liability of our directors will be further limited to the greatest extent permitted by the DGCL. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-15 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="stoc201932_10"></a>PLAN OF DISTRIBUTION </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a Sales Agreement, dated as of February&#160;16, 2018 and amended on November&#160;9, 2020, with SVB Leerink under which
we may issue and sell up to $50,000,000 of our common stock from time to time through SVB Leerink acting as our sales agent. In this prospectus, we refer to a prior sales agreement prospectus supplement dated February&#160;16, 2018 as the prior
prospectus supplement. The prior prospectus supplement provided for sales of shares of our common stock having an aggregate offering price of up to $50,000,000. As of the date of this prospectus, we had issued and sold shares of common stock
pursuant to the Sales Agreement and the prior prospectus supplement for which we had received gross proceeds of approximately $18,205,969 and $31,794,031 remained unsold. The common stock remaining available to be sold under the prior prospectus
supplement as of the date of this prospectus will no longer be offered and sold under the prior prospectus supplement, but will instead be offered and sold under this prospectus. Accordingly, this prospectus covers the offer and sale of up to
$31,794,031 of our common stock that may be sold under the Sales Agreement as of the date of this prospectus. Sales of our common stock, if any, will be made by any method that is deemed to be an &#147;at the market offering&#148; as defined in
Rule&#160;415(a)(4) under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on or through the Nasdaq Capital Market or on or through any other existing trading market for the common stock. The Sales
Agreement is filed as an exhibit to the registration statement of which this prospectus forms a part and is incorporated by reference in this prospectus. The following summary of the material provisions of the Sales Agreement does not purport to be
a complete statement of its terms and conditions. See &#147;Where You Can Find More Information&#148; and &#147;Information Incorporated by Reference&#148; below. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon delivery of a placement notice, SVB Leerink will offer our common stock subject to the terms and conditions of the Sales Agreement on a
daily basis or as otherwise agreed upon by us and SVB Leerink. We will designate the maximum number or amount of common stock to be sold through SVB Leerink on a daily basis or otherwise determine such maximum number or amount together with SVB
Leerink. Subject to the terms and conditions of the Sales Agreement, SVB Leerink will use commercially reasonable efforts consistent with its normal trading and sales practices to sell on our behalf all of the common stock requested to be sold by
us. We may instruct SVB Leerink not to sell common stock if the sales cannot be effected at or above a minimum price designated by us in any such instruction. SVB Leerink or we may suspend the offering of our common stock being made through SVB
Leerink under the Sales Agreement upon proper notice to the other party. SVB Leerink and we each have the right, by giving written notice as specified in the Sales Agreement, to terminate the Sales Agreement in each party&#146;s sole discretion at
any time. The offering of our common stock pursuant to the Sales Agreement will otherwise terminate upon the termination of the Sales Agreement as provided therein. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation payable to SVB Leerink as sales agent will be an amount up to 3.0% of the gross proceeds of any shares of common stock sold
through it pursuant to the Sales Agreement. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this
time. We have also reimbursed SVB Leerink for actual outside legal expenses incurred by SVB Leerink in connection with this offering of $50,000. In accordance with FINRA Rule&#160;5110, these reimbursed fees and expenses are deemed sales
compensation to SVB Leerink in connection with this offering. We estimate that the total expenses of the offering payable by us, excluding commissions payable to SVB Leerink under the Sales Agreement, will be approximately $300,000. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory or
self-regulatory organization in connection with the sales of our common stock, will equal our net proceeds for the sale of such common stock. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink will provide written confirmation to us no later than the next succeeding trading day on the Nasdaq Capital Market after each day
on which common stock is sold through it as sales agent under the Sales Agreement. Each confirmation will include the number or amount of shares sold through it as sales agent on that </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-16 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
day, the compensation payable by us to SVB Leerink with respect to such sales, and the net proceeds to us from such sales. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will report at least quarterly the number of shares of common stock sold through SVB Leerink under the Sales Agreement, the net proceeds to
us and the compensation paid by us to SVB Leerink in connection with the sales of common stock during the relevant period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Settlement for
sales of common stock will occur, unless the parties agree otherwise, on the second trading day following the date on which any sales were made in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an
escrow, trust or similar arrangement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of the common stock on our behalf pursuant to the Sales Agreement, SVB
Leerink will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation paid to SVB Leerink will be deemed to be underwriting commissions or discounts. We have agreed in the Sales Agreement to provide
indemnification and contribution to SVB Leerink with respect to certain liabilities, including liabilities under the Securities Act or the Exchange Act. As sales agent, SVB Leerink will not engage in any transactions that stabilize our common stock.
</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market and trades under the symbol &#147;AVEO&#148;. The transfer agent of our common
stock is Computershare Trust Company, N.A. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink and/or its affiliates have provided, and may in the future provide, various
investment banking and other financial services for us for which services they have received, and may in the future receive, customary fees. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-17 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="stoc201932_11"></a>LEGAL MATTERS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities in respect of which this prospectus is being delivered will be passed upon by Wilmer Cutler Pickering Hale and
Dorr LLP, Boston, Massachusetts. Cooley LLP, New York, New York, is counsel to SVB Leerink in connection with this offering. </p> <p align="center" style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="stoc201932_12">
</a>EXPERTS </b></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of AVEO Pharmaceuticals, Inc. appearing in AVEO Pharmaceuticals, Inc.&#146;s Annual
Report (Form <font style="white-space:nowrap">10-K)</font> for the year ended December&#160;31, 2019 and the effectiveness of AVEO Pharmaceuticals, Inc.&#146;s internal control over financial reporting as of December&#160;31, 2019 have been audited
by Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, as set forth in its reports thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about AVEO Pharmaceuticals, Inc.&#146;s
ability to continue as a going concern as described in Note 1 to the consolidated financial statements), and incorporated herein by reference. Such financial statements have been incorporated herein by reference in reliance upon such reports given
on the authority of such firm as experts in accounting and auditing. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-18 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="stoc201932_13"></a>WHERE YOU CAN FIND MORE INFORMATION </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#146;s website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at http://www.aveooncology.com/. Our website is not a part of this prospectus and is
not incorporated by reference in this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. This
prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our
consolidated subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and
are qualified by reference to these filings. You should review the complete document to evaluate these statements. </p> <p align="center" style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="stoc201932_14">
</a>INCORPORATION BY REFERENCE </b></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference much of the information we file with the SEC, which
means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are
incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all
of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the
documents listed below (File <font style="white-space:nowrap">No.&#160;001-34655)</font> and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act (in
each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the
registration statement until the offering of the securities under the registration statement is terminated or completed: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on <a href="http://www.sec.gov/Archives/edgar/data/1325879/000156459020011145/aveo-10k_20191231.htm">Form
 <font style="white-space:nowrap">10-K</font></a> for the fiscal year ended December&#160;31, 2019, including the information specifically incorporated by reference into the Annual Report on Form <font style="white-space:nowrap">10-K</font> from our
definitive proxy statement for the 2020 Annual Meeting of Stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly Reports on Form <font style="white-space:nowrap">10-Q</font> for the fiscal quarters ended <a href="http://www.sec.gov/Archives/edgar/data/1325879/000156459020019921/aveo-10q_20200331.htm">March&#160;31,
 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/1325879/000156459020038899/aveo-10q_20200630.htm">June&#160;
30, 2020</a> and <a href="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1325879/000156459020052556/aveo-10q_20200930.htm">September&#160;30, 2020</a>; </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on Form <font style="white-space:nowrap">8-K</font> filed on <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520002244/d863683d8k.htm">January&#160;6,
 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520035652/d881309d8k.htm">February&#160;13, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520042086/d806743d8k.htm">February&#160;
19, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520153095/d936328d8k.htm">May&#160;27, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520155052/d889663d8k.htm">May&#160;29, 2020</a> (Item
8.01 only), <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520157210/d904464d8k.htm">June&#160;1, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520165801/d929481d8k.htm">June&#160;
10, 2020</a>, <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520169515/d885511d8k.htm">June&#160;15, 2020</a> (Item 8.01 only), <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520171457/d942122d8k.htm">June&#160;
17, 2020</a> and <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520240516/d80039d8k.htm">September&#160;8, 2020</a>; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="5%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our Registration Statement on <a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312510051398/d8a12b.htm">Form
 <font style="white-space:nowrap">8-A</font></a> filed on March&#160;9, 2010, including any amendments or reports filed for the purpose of updating such description. </p></td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </p>
<p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AVEO Pharmaceuticals, Inc. </p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30
Winter Street </p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02108 </p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Investor Relations </p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(857) <font style="white-space:nowrap">400-0101</font> </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SA-19 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&#160;</p>
<p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<p align="center" style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="https://www.sec.gov/Archives/edgar/data/0001325879/000119312520289207/g201932g11k45.jpg"/>
</p> <p align="center" style="margin-top:48pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><b>$31,794,031 </b></p>
<p align="center" style="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Common Stock </b></p> <p style="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center> <p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><b>PROSPECTUS
</b></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:48pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><b>SVB Leerink </b></p> <p style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<p style="font-size:100pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2020 </b></p>
<p style="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p>
<p style="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&#160;</p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>PART II </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>INFORMATION NOT REQUIRED IN PROSPECTUS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Item&#160;14. Other Expenses of Issuance and Distribution. </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below are estimates (except in the case of the Securities and Exchange Commission, or SEC, and Financial Industry Regulatory
Authority, or FINRA, registration fees) of the amount of fees and expenses to be incurred in connection with the issuance and distribution of the offered securities, other than underwriting discounts and commissions. </p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="68%">
<tr>
<td width="85%"></td>
<td valign="bottom" width="7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr bgcolor="#cceeff" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">$</td>
<td align="right" valign="bottom">32,730</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving fees</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">(1</td>
<td nowrap="" valign="bottom">)&#160;</td></tr>
<tr bgcolor="#cceeff" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">(1</td>
<td nowrap="" valign="bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">(1</td>
<td nowrap="" valign="bottom">)&#160;</td></tr>
<tr bgcolor="#cceeff" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">(1</td>
<td nowrap="" valign="bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">$</td>
<td align="right" valign="bottom">(1</td>
<td nowrap="" valign="bottom">)&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td align="left" valign="top" width="4%">(1)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">These fees and expenses are calculated based on the securities offered and the number of issuances and
accordingly are not estimated at this time and will be reflected in the applicable prospectus supplement. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Item&#160;15.
Indemnification of Directors and Officers. </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the General Corporation Law of the State of Delaware, or the DGCL,
provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of
the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in
connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or
proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action
or suit by or in the right of the corporation, <i>provided</i> that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues
and matters as to which such person shall have been adjudged liable to the corporation, <i>provided</i> that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the
case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;102(b)(7) of the DGCL provides, generally, that our certificate of incorporation may contain a provision eliminating or limiting
the personal liability of a director to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director, <i>provided</i> that such provision may not eliminate or limit the liability of a director (i)&#160;for any
breach of the director&#146;s duty of loyalty to the corporation or its shareholders, (ii)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;under Section&#160;174 of the
DGCL, or (iv)&#160;for any transaction from which the director derived an improper personal benefit. No such provision may eliminate or limit the liability of a director for any act or omission occurring prior to the date when such provision became
effective. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that we will indemnify each person who was or is a party or threatened to be made a
party to any threatened, pending or completed action, suit or proceeding whether civil, criminal, administrative or investigative (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to
become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">II-1 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or
omitted in such capacity, against all expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the Indemnitee or on his or her behalf in connection with such action, suit or
proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no
reasonable cause to believe his or her conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption
that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his or her
conduct was unlawful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation also provides that we will indemnify any Indemnitee who was or is a party or
threatened to be made a party to any threatened, pending or completed action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, our director or officer,
or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any
action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action,
suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any
claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless and only to the extent that a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to
indemnification for such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#146; fees) actually
and reasonably incurred by him or her or on his or her behalf in connection therewith. If we don&#146;t assume the defense, expenses must be advanced to an Indemnitee under certain circumstances. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a general liability insurance policy which covers certain liabilities of our directors and officers arising out of claims based on
acts or omissions in their capacities as directors or officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <font style="white-space:nowrap">non-employee</font>
directors may, through their relationships with their employers, be insured and/or indemnified against certain liabilities in their capacity as members of our board of directors. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Item&#160;16. Exhibits. </b></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr>
<td></td>
<td valign="bottom" width="5%"></td>
<td width="91%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" nowrap="" valign="bottom"> <p align="center" style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><b>Exhibit<br/>No.</b></p></td>
<td valign="bottom">&#160;&#160;</td>
<td align="center" nowrap="" valign="bottom"> <p align="center" style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><b>Description</b></p></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;1.1*</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">Form of Underwriting Agreement</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;1.2</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312518048574/d530363dex11.htm">Sales Agreement, dated February&#160;
16, 2018, by and between the Registrant and Leerink Partners LLC (incorporated by reference to Exhibit 1.1 to the Registrant&#146;s Current Report on Form <font style="white-space:nowrap">8-K</font> filed on February&#160;16, 2018 (File <font style="white-space:nowrap">No.&#160;001-34655)).</font> </a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;1.3</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312520289207/d201932dex13.htm">Amendment No.&#160;1 to the Sales Agreement, dated November&#160;9, 2020, by and between the Registrant and SVB Leerink LLC </a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.1</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="http://www.sec.gov/Archives/edgar/data/1325879/000156459019030755/aveo-ex31_201.htm">Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Quarterly
 Report on Form <font style="white-space:nowrap">10-Q</font> filed on August&#160;8, 2019 (File <font style="white-space:nowrap">No.&#160;001-34655)).</font> </a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.2</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312520042086/d806743dex31.htm">Certificate of Amendment of Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s
 Current Report on Form <font style="white-space:nowrap">8-K</font> filed on February&#160;19, 2020 (File <font style="white-space:nowrap">No.&#160;001-34655)).</font> </a></td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">II-2 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr>
<td></td>
<td valign="bottom" width="6%"></td>
<td width="91%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" nowrap="" valign="bottom"> <p align="center" style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><b>Exhibit<br/>No.</b></p></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><b>Description</b></p></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.3</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312510024516/dex35.htm">Second Amended and Restated <font style="white-space:nowrap">By-laws</font> of the Registrant (incorporated by reference to Exhibit 3.5 to the Registrant&#146;s
 Registration Statement on Form <font style="white-space:nowrap">S-1,</font> as amended, filed on February&#160;8, 2010 (File <font style="white-space:nowrap">No.&#160;333-163778)).</font> </a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.4</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312520289207/d201932dex44.htm">Form of Senior Indenture </a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.5</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312520289207/d201932dex45.htm">Form of Subordinated Indenture </a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.6</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312520289207/d201932dex46.htm">Form of Senior Note </a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.7</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312520289207/d201932dex47.htm">Form of Subordinated Note </a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.8*</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">Form of Warrant Agreement</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.9*</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">Form of Unit Agreement</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;5.1</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312520289207/d201932dex51.htm">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP </a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">23.1</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312520289207/d201932dex231.htm">Consent of Ernst&#160;&amp; Young LLP, independent registered public accounting firm for the Registrant </a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">23.2</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312520289207/d201932dex51.htm">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1) </a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">24.1</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="#sig">Powers of Attorney (included in the signature pages to the Registration Statement) </a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">25.1**</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">Statement of Eligibility on Form <font style="white-space:nowrap">T-1</font> under the Trust Indenture Act of 1939, as amended, of the Trustee under the Senior Indenture</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">25.2**</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">Statement of Eligibility on Form <font style="white-space:nowrap">T-1</font> under the Trust Indenture Act of 1939, as amended, of the Trustee under the Subordinated Indenture</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td align="left" valign="top" width="4%">*</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">To be filed by amendment or by a Current Report on Form <font style="white-space:nowrap">8-K.</font>
</p></td></tr></table>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td align="left" valign="top" width="4%">**</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">To be filed pursuant to Section&#160;305(b)(2) of the Trust Indenture Act of 1939. </p></td></tr></table>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Item&#160;17. Undertakings. </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
undersigned Registrant hereby undertakes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="7%">&#160;</td>
<td align="left" valign="top" width="6%">(a)(1)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="13%">&#160;</td>
<td align="left" valign="top" width="5%">(i)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">to include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="13%">&#160;</td>
<td align="left" valign="top" width="5%">(ii)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">to reflect in the prospectus any facts or events arising after the effective date of this registration
statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of
prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20&#160;percent change in the maximum aggregate offering price set forth in the &#147;Calculation of
Registration Fee&#148; table in the effective registration statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="13%">&#160;</td>
<td align="left" valign="top" width="5%">(iii)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">to include any material information with respect to the plan of distribution not previously disclosed in this
registration statement or any material change to such information in this registration statement; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><i>provided</i>, <i>however</i>, that
paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to
</p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">II-3 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Commission by the Registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), that are incorporated by
reference in this registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of this registration statement. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="5%">(2)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">That, for the purposes of determining any liability under the Securities Act, each such post-effective
amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at the time shall be deemed to be the initial <i>bona fide</i> offering thereof. </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="5%">(3)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="5%">(4)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">That, for the purpose of determining liability under the Securities Act to any purchaser:
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="9%">&#160;</td>
<td align="left" valign="top" width="4%">(i)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="9%">&#160;</td>
<td align="left" valign="top" width="4%">(ii)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x)&#160;for the purpose of providing the information required by Section&#160;10(a) of the Securities Act shall be deemed to be part of and
included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule
430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that
prospectus relates, and the offering of such securities at that time shall be deemed to be the initial <i>bona fide</i> offering thereof. <i>Provided, however</i>, that no statement made in a registration statement or prospectus that is part of the
registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to
such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="5%">(5)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">That, for the purpose of determining liability of the Registrant under the Securities Act to any purchaser in
the initial distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the
securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such
securities to such purchaser: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="9%">&#160;</td>
<td align="left" valign="top" width="4%">(i)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be
filed pursuant to Rule 424; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="9%">&#160;</td>
<td align="left" valign="top" width="4%">(ii)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or
used or referred to by the undersigned Registrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="9%">&#160;</td>
<td align="left" valign="top" width="4%">(iii)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">the portion of any other free writing prospectus relating to the offering containing material information about
the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="9%">&#160;</td>
<td align="left" valign="top" width="4%">(iv)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.
</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="5%">(b)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">That, for purposes of determining any liability under the Securities Act, each filing of the Registrant&#146;s
annual report pursuant to Section&#160;13(a) or 15(d) of the Exchange Act (and, where applicable, each </p></td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">II-4 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="9%">&#160;</td>
<td align="left" valign="top">
filing of an employee benefit plan&#146;s annual report pursuant to Section&#160;15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <i>bona fide</i> offering thereof. </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="5%">(c)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the Registrant pursuant to the indemnification provisions described herein, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="5%">(6)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">That, for purposes of determining any liability under the Securities Act: </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="9%">&#160;</td>
<td align="left" valign="top" width="4%">(i)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">the information omitted from the form of prospectus filed as part of the registration statement in reliance
upon Rule 430A and contained in the form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&#160;or 497(h) under the Securities Act shall be deemed to be part of the registration statement as of the time it was declared
effective; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="9%">&#160;</td>
<td align="left" valign="top" width="4%">(ii)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <i>bona fide</i> offering thereof. </p></td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="5%">(c)</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; ">The undersigned Registrant hereby undertake to file an application for the purpose of determining the
eligibility of the trustee to act under subsection (a)&#160;of Section&#160;310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Commission under Section&#160;305(b)(2) of the Trust Indenture Act.
</p></td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">II-5 </p>
</div></center>
<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>SIGNATURES </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, or the Securities Act, the Registrant certifies that it has reasonable
grounds to believe that it meets all of the requirements for filing on Form <font style="white-space:nowrap">S-3</font> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the
city of Boston, Commonwealth of Massachusetts, on November&#160;9, 2020. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div align="right">
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="40%">
<tr>
<td width="7%"></td>
<td valign="bottom" width="1%"></td>
<td width="92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" valign="top">AVEO PHARMACEUTICALS, INC.</td></tr>
<tr style="font-size:1pt">
<td height="16"></td>
<td colspan="2" height="16"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top">By:</td>
<td valign="bottom">&#160;</td>
<td valign="top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Bailey</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"></td>
<td valign="bottom">&#160;</td>
<td valign="bottom">Name: Michael Bailey</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"></td>
<td valign="bottom">&#160;</td>
<td valign="bottom">Title: President&#160;&amp; Chief Executive Officer</td></tr>
</table></div> <p align="center" style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="sig"></a>SIGNATURES AND POWER OF ATTORNEY </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the undersigned officers and directors of AVEO Pharmaceuticals, Inc. hereby severally constitute and appoint Michael Bailey and Erick
Lucera, and each of them singly, our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the Registration Statement on Form <font style="white-space:nowrap">S-3</font> filed herewith and any and all amendments (including post-effective amendments) to said Registration Statement, and any registration statement filed pursuant to Rule 462 under the Securities Act, in connection
with said Registration Statement, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all such things in our name and on
our behalf in our capacities as officers and directors to enable AVEO Pharmaceuticals, Inc. to comply with the provisions of the Securities Act, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming all that
said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr>
<td width="39%"></td>
<td valign="bottom" width="1%"></td>
<td width="39%"></td>
<td valign="bottom" width="2%"></td>
<td width="18%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" nowrap="" valign="bottom"> <p align="center" style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Signature</p></td>
<td valign="bottom">&#160;&#160;</td>
<td align="center" nowrap="" valign="bottom"> <p align="center" style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Title</p></td>
<td valign="bottom">&#160;</td>
<td align="center" nowrap="" valign="bottom"> <p align="center" style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Date</p></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Bailey</p>
<p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Michael Bailey</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">President, Chief Executive Officer and Director (Principal Executive Officer)</td>
<td valign="bottom">&#160;</td>
<td valign="top">November&#160;9, 2020</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Erick Lucera</p>
<p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Erick Lucera</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">Chief Financial Officer (Principal Financial and Accounting Officer)</td>
<td valign="bottom">&#160;</td>
<td valign="top">November&#160;9, 2020</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kenneth M. Bate</p>
<p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kenneth M. Bate</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">Director</td>
<td valign="bottom">&#160;</td>
<td valign="top">November&#160;9, 2020</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Anthony B. Evnin</p>
<p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Anthony B. Evnin</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">Director</td>
<td valign="bottom">&#160;</td>
<td valign="top">November&#160;9, 2020</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert C. Young</p>
<p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Robert C. Young</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">Director</td>
<td valign="bottom">&#160;</td>
<td valign="top">November&#160;9, 2020</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gregory T. Mayes</p>
<p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Gregory T. Mayes</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">Director</td>
<td valign="bottom">&#160;</td>
<td valign="top">November&#160;9, 2020</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scarlett Spring</p>
<p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Scarlett Spring</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">Director</td>
<td valign="bottom">&#160;</td>
<td valign="top">November&#160;9, 2020</td></tr>
</table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">II-6 </p>
</div></center>
</text>
</description></filename></sequence></type></document>
</body></html>